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Abstract 
We recently demonstrated that SB269652 (1) engages one protomer of a dopamine D2 
receptor (D2R) dimer in a bitopic mode to allosterically inhibit the binding of dopamine at the 
other protomer. Herein, we investigate structural determinants for allostery, focusing on 
modifications to three moieties within 1. We find that orthosteric ‘head’ groups with small 7-
substituents were important to maintain the limited negative cooperativity of analogues of 1, 
and replacement of the tetrahydroisoquinoline head group with other D2R ‘privileged 
structures’ generated orthosteric antagonists. Additionally, replacement of the cyclohexylene 
linker with polymethylene chains conferred linker length dependency in allosteric 
pharmacology. We validated the importance of the indolic NH as a hydrogen-bond donor 
moiety for maintaining allostery. Replacement of the indole ring with azaindole conferred a 
30-fold increase in affinity whilst maintaining negative cooperativity. Combined, these 
results provide novel SAR insight for bitopic ligands that act as negative allosteric 
modulators of the D2R. 
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Introduction 
The dopamine D2 receptor (D2R), a class A G protein-coupled receptor (GPCR), is a 
therapeutic target for central nervous system disorders including schizophrenia and 
Parkinson’s disease.1 To date, drug discovery at this target has focused on the orthosteric 
binding site, with clinically marketed antipsychotics being either antagonists/inverse agonists 
or partial agonists at the D2R.
2 Unfortunately, such approaches are associated with significant 
side effects; in particular, high occupancy orthosteric blockade of the D2R provided by first 
generation antipsychotics, while effective in treating the positive symptoms of the disease, is 
associated with extrapyramidal side effects.2  
It has become apparent that many class A GPCRs have at least one other topographically 
distinct, allosteric binding site that can be targeted by small molecules.3-6 Ligands that behave 
as allosteric modulators may offer advantages over purely orthosteric ligands, including 
increased receptor subtype selectivity and maintenance of spatiotemporal patterns associated 
with the signals of the endogenous ligand.7 These features make negative allosteric 
modulators an attractive prospect for the treatment of schizophrenia, where partial blockade 
by a negative allosteric modulator with limited negative cooperativity, may represent a safer 
therapeutic option for the positive symptoms of schizophrenia.8 More recently, concomitantly 
targeting both orthosteric and allosteric sites with bitopic ligands, in which allosteric and 
orthosteric pharmacophores have been linked together, has been explored as a means of 
developing more selective GPCR ligands.9-11  
SB269652 (1)12,13 was recently described as the first small molecule negative allosteric 
modulator of the D2R.
13 This was somewhat surprising, given that 1 contains structural 
features of numerous orthosteric D2-like receptor ligands.
12,14-16 Indeed, the 1,2,3,4-
tetrahydroisoquinoline (THIQ) ‘head’ group of 1 contains a basic tertiary amine that is 
expected to form a salt bridge with the conserved aspartate (Asp3.32, Ballosteros-Weinstein 
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nomenclature17) of aminergic GPCRs, and would thus compete with the binding of dopamine. 
The lipophilic 1H-indole-2-carboxamide ‘tail’ group is characteristic of the lipophilic 
appendages that are a feature of numerous subtype selective D2-like receptor ligands.
14 Such 
appendages have been proposed to extend into a secondary pocket away from the orthosteric 
pocket.14,18,19  
We have recently confirmed that 1 displays limited negative allosteric cooperativity at the 
D2R with a sub-micromolar binding affinity, but found that truncated derivatives of 1 
containing a THIQ moiety act in a competitive manner with dopamine.20 We demonstrated 
that 1 acts via a novel mechanism, engaging one protomer of a D2R dimer in a dual 
orthosteric/allosteric (or bitopic) mode, to negatively modulate dopamine binding and 
function at the other protomer (Figure 1).20 This mechanism allowed us to reconcile an 
orthosteric mode of interaction with the allosteric pharmacology of SB26965. Furthermore, 
the interaction of the 1H-indole-2-carboxamide moiety of 1 with a secondary, or allosteric, 
pocket between the extracellular face of transmembrane domains (TMs) 2 and 7, was shown 
to be a requirement for the allosteric pharmacology of 1. These findings presented a novel 
mode of action for small molecules at this therapeutically important target.21 Additionally, we 
were able to use 1 as a probe to identify D2R dimers in rat striatal tissue, adding to previous 
evidence that this receptor can function as a dimer or oligomer.22-26 It should be noted that the 
above mechanism differs from previous studies that attempted to target D2R 
dimers/oligomers using bivalent ligands that simultaneously occupy binding sites on two 
adjacent receptors.27,28  
 
<Insert Figure 1> 
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Currently, there is limited SAR data associated with 1, indicating scope for further 
structural interrogation (Figure 2). We therefore undertook a study to identify novel negative 
allosteric modulators for the D2R, based on the structure of 1. In particular, given the 
similarity of 1 to other D2-like selective ligands
14,29 that display competitive pharmacology 
with dopamine, it is important to understand the key structural features of 1 that underlie its 
distinct allosteric pharmacology. Through modifications to the scaffold of 1, as illustrated in 
Figure 2, we aimed to identify key molecular features that were responsible for changes in 
functional affinity and negative allosteric cooperativity, thereby enhancing our understanding 
of the nature of this bitopic mechanism and of allostery at the D2R.  
 
<Insert Figure 2> 
 
Synthesis 
We generated a focused library of analogues of 1 to examine the effect on functional 
affinity and allosteric pharmacology of the scaffold, as depicted in Figure 2. These included  
replacement of the 7-cyano group with various substituents of differing size and electronic 
effects (H, F, Cl, Br and CF3); replacement of the THIQ core with D2R privileged motifs and 
related bicyclic systems (2,3,4,5-tetrahydro-1H-benzo[c]azepine, 4,5,6,7-
tetrahydrothieno[3,2-c]pyridine, 1-(2-methoxyphenyl)piperazine (2-MPP) and 1-(2,3-
dichlorophenyl)piperazine (2,3-DCPP)); and the installation of polymethylene spacers in 
place of the cyclohexylene linker. We also explored the role of hydrogen-bond donors in 1 by 
examining the effect of alkylation of both the indolic and carboxamide NH moieties, and by 
investigating the influence of various heteroatoms on the tail group. In addition, we sought to 
evaluate the impact of replacing the indole moiety with monocyclic (e.g. pyrrole and 
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pyrrolidine) and various electron-rich and electron-deficient bicyclic (e.g. benzofuran and 
azaindole, respectively) heterocyclic systems. 
The synthesis of all compounds generally followed previously established methods for the 
synthesis of 1,12,20 and other related compounds recently reported by our research group.30 
For the synthesis of compounds with modifications to the THIQ core, various 
tetrahydroisoquinolines, phenylpiperazines, or tetrahydrothienopyridine, were commercially 
sourced. The compound 2,3,4,5-tetrahydro-1H-benzo[c]azepine (4) was synthesized by a 
Schmidt reaction of 1-tetralone (2) in concentrated hydrochloric acid, favouring the alkyl-
migration lactam 3 as the major product,31 shown in Scheme 1. Reduction of 3 with lithium 
aluminium hydride gave 4 in good yield.  
 
<Insert Scheme 1> 
 
The preparation of the trans-cyclohexylene spacer unit, illustrated in Scheme 2, followed 
methods that we previously reported, to afford aldehyde 8 from 4-nitrophenylacetic acid 
(5).30 The preparation of 1 from 8 was carried out using literature procedures.12,20 Compound 
8 was treated under reductive alkylation conditions (NaBH(OAc)3) with the various 
secondary amine head groups (9b-j), which were prepared as in Scheme 1, or commercially 
supplied as the free base or hydrochloride salt. In the case where hydrochloride salts were 
used, N,N-diisopropylethylamine (DIPEA, Hünig’s base) was also added to liberate the free 
base. This process afforded the corresponding tertiary amines (10b-j). Deprotection of the N-
Boc group in TFA/DCM, followed by basic workup or 4 M HCl/1,4-dioxane, afforded the 
primary amines (11a, c-h) or the corresponding dihydrochloride (11b) or trihydrochloride 
salts (11i-j), respectively. The final compounds (12b-j) were then prepared by treatment of 
11b-j with 1H-indole-2-carboxylic acid in the presence of O-(6-chlorobenzotriazol-1-yl)-
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N,N,N′,N′-tetramethyluronium hexafluorophosphate  (HCTU) and DIPEA, as presented in 
Scheme 2.  
 
<Insert Scheme 2> 
 
We next explored compounds with modifications to the spacer group of 1, as illustrated in 
Scheme 3, using various starting points depending on commercial availability. For the 
synthesis of the propylene spacer, 3-bromopropylamine hydrobromide (13a) underwent N-
Boc protection, before alkylation with 7-cyano-1,2,3,4-tetrahydroisoquinoline (7-CTHIQ, 9a) 
in the presence of K2CO3 in refluxing MeCN, in moderate yield. For the synthesis of 
compounds with butylene, pentylene and hexylene spacers, the appropriate aminoalcohol 
(13b-d) underwent N-Boc protection, followed by activation of the alcohol using 
methanesulfonyl chloride, and subsequent nucleophilic substitution with 9a. The N-Boc-
protected compounds 16a-d underwent deprotection with TFA, prior to HCTU-mediated 
coupling with 1H-indole-2-carboxylic acid to give the final products, 18a-d.  
 
<Insert Scheme 3> 
 
In order to explore the requirements of the 1H-indole-2-carboxamide tail group for 
allosteric pharmacology, we generated a number of analogues of 1 bearing structural  
modifications to the tail moiety. To assess the role of the amide NH in a hydrogen-bond 
donating interaction, we synthesised the N-methylated indole-2-carboxamide analogue (23), 
which removes one potential hydrogen-bond donor present in 1. For the synthesis of 23, ethyl 
2-(trans-4-((tert-butoxycarbonyl)amino)cyclohexyl)acetate (7), was N-methylated using an 
excess of sodium hydride and iodomethane in DMF over 3 days (Scheme 4), and ester 19 
was isolated in moderate yield. This method was chosen in favor of Eschweiler-Clarke 
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methylation of amine 6 due to the large scale of 7 that was already synthesized, and was 
readily accessible for further reactions. 19 was subsequently reduced using DIBAL-H to the 
corresponding aldehyde (20), before reductive alkylation with 9a in the presence of 
NaBH(OAc)3 to give 21. The N-Boc group was then removed with TFA in DCM to give 
secondary amine 22, which was coupled with 1H-indole-2-carboxylic acid in the presence of 
HCTU to give the desired N-methylated product (23). 
 
<Insert Scheme 4> 
To further our understanding of a hydrogen-bonding interaction between the 1H-indole-2-
carboxamide moiety of 1 and Glu952.65, as we have previously described,20 we generated 
compounds which were completely devoid of a hydrogen-bond donor group on the indole 
moiety. To do this, we generated the benzofuran-2-carboxamide (25a), benzo[d]oxazole-2-
carboxamide (25b), 1H-indene-2-carboxamide (25c) and 1-methyl-1H-indole-2-carboxamide 
(25d) analogues. We also investigated analogues which ‘fine-tuned’ the hydrogen-bond 
donating ability by modifying the electronic properties of the indole moiety, namely by the 
synthesis of the 1H-benzo[d]imidazole-2-carboxamide (25e) and 1H-pyrrolo[2,3-b]pyridine-
2-carboxamide (25f) analogues. The synthesis of these compounds, depicted in Scheme 5, 
required coupling of the primary amine 11a with the appropriate commercially available 
carboxylic acid analogues (benzofuran-2-carboxylic acid (24a), potassium benzo[d]oxazole-
2-carboxylate (24b), 1H-indene-2-carboxylic acid (24c), 1-methyl-1H-indole-2-carboxylic 
acid (24d), benzo[d]imidazole-2-carboxylic acid (24e), 1H-pyrrolo[2,3-b]pyridine-2-
carboxylic acid (24f) in the presence of HCTU and DIPEA, to furnish the desired final 
products (25a-f).  
To explore the requirement of steric bulk and aromaticity in the tail group, we generated 
the ring-deleted pyrrole analogue (26), as seen in Scheme 6. Furthermore, we generated the 
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D- (27b) and L-proline (27b) analogues which remove all aromaticity and planarity, and 
introduces an ionisable nitrogen to the tail group. The synthesis of 26, as seen in Scheme 6, 
required coupling of amine 11a with pyrrole-2-carboxylic acid in the presence of EDCI and 
DMAP in DCM, which afforded 26 in moderate yield. The proline analogues (27b and 28b) 
were synthesized by coupling of 11a with commercially supplied N-Boc-D- and N-Boc-L-
proline, respectively, in the presence of HCTU and DIPEA in DMF, and was immediately 
followed by N-Boc deprotection to afford 27b and 28b, as shown in Scheme 6. 
 
<Insert Scheme 5> 
 
<Insert Scheme 6> 
 
Results and Discussion 
All compounds were tested for their ability to bind the D2R in a competition binding assay 
using the antagonist [3H]raclopride. For competitive ligands, a value of affinity (KB) was 
derived. However, some ligands were unable to completely inhibit the binding of 
[3H]raclopride even at saturating concentrations, consistent with an allosteric mode of 
interaction (Figure 3A, Tables 1-4). In these cases, data were fit using an allosteric ternary 
complex to derive a value of affinity, denoted as KB, and cooperativity with [
3H]raclopride 
(α). However, this assay does not provide information regarding the effect of compounds 
upon the neurotransmitter dopamine. Therefore, the activity of all compounds was tested in 
an assay measuring phosphorylation of ERK1/2 through activation of the long isoform of the 
D2R (D2LR) expressed in FlpIn CHO cells. This assay provides a robust, medium throughput 
measurement of D2R activation. Compounds were tested for their ability to antagonize the 
action of increasing concentrations of dopamine. An example of these data is presented in 
Figure 3B. These data were fit with either a derivation of the operational model of 
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allosterism32 (see supplementary information) to derive values of functional affinity (denoted 
as KB), and allosteric cooperativity with dopamine (denoted as αβ, a composite parameter 
where α is negative cooperativity with dopamine binding, and β denotes modulation of 
dopamine efficacy); a Gaddum-Schild model of competitive antagonism to derive values of 
functional affinity (KB); and, a Schild slope, where a Schild slope that is not significantly 
different from unity (Schild slope = 1) indicates competitive antagonism. For each 
compound, data were analysed with both models and the best fit determined by an F-test. 
These data are reported in Tables 1-4 and are presented as logarithms to allow statistical 
comparison.33 Values of Logαβ < 0 signify negative cooperativity with dopamine. The 
overall correlation between the values of affinity obtained in the functional and binding 
assays was good (R2 = 0.73, Supplementary figure 1). Therefore, because we were most 
interested in the functional effect of 1 and its analogues upon the action of dopamine, we 
focus upon these data for structure-activity analysis. The lead compound (1) acted as a 
negative allosteric modulator at the D2R, with moderate functional affinity (KB = 776 nM). 
The limited dextral displacement of the dopamine dose-response curve by increasing 
concentrations of 1 is characteristic of the action of a negative allosteric modulator, and the 
value of negative cooperativity (Logαβ = -1.23 ± 0.14) translates to a maximal 17-fold 
decrease in dopamine potency (Figure 3B, Table 1). 
<Insert Tables 1-4> 
We first examined modifications to the 7-CTHIQ-containing head group of 1 (Table 1). 
Stemp et al.12 incorporated the 7-cyano substituent to deactivate the THIQ ring system for the 
purposes of reducing in vivo metabolism, thus increasing oral bioavailability. We determined 
that replacement of the nitrile group with hydrogen (12b) resulted in a significant 9-fold 
increase in functional affinity (KB = 87 nM), but no significant change to allosteric 
cooperativity (Logαβ = -1.04 ± 0.14) at the D2R (Table 1). To further explore the effect of 
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atomic size and electronegativity in the 7-position, we generated a series of 7-halogeno 
analogues of 1. The 7-fluoro analogue (12c) resulted in no significant change in functional 
affinity (KB =1.05 µM) compared to 1, whilst displaying weaker negative allosteric 
cooperativity (Logαβ = -0.69 ± 0.10). A chloro substituent at the 7-position (12d) had a 
similar effect to 12c, with no significant change in functional affinity (KB = 2.04 µM) and 
significantly diminished negative allosteric cooperativity (Logαβ = -0.66 ± 0.10, Table 1) 
relative to 1. While incorporation of a 7-bromo group (12e) resulted a significant gain in 
functional affinity (KB = 138 nM), increasing concentrations of this compound caused a 
limitless dextral shift of the dopamine dose-response curve that was best fit by a competitive 
mode of interaction (Figure 3C) although the Schild slope was less than unity (Table 1). 
Similarly, incorporation of a trifluoromethyl group at the 7-position (12f) resulted in a change 
in pharmacology from allosteric to competitive antagonism but maintained a functional 
affinity (KB = 891 nM) comparable to 1. These modifications demonstrate that the size and 
degree of electronegativity of the 7-substituent may be an important determinant of both 
functional affinity and negative cooperativity. Indeed, a comparison of the van der Waals 
(vdW) radii34 of the substituent in the 7-position suggests that smaller substituents are more 
optimal for maintaining allosteric pharmacology, whereas the inductive effect of the 
substituent35 has less relationship to functional affinity or allosteric pharmacology. The 7-
fluoro (12c) and 7-trifluoromethyl (12f) analogues both exhibit a similar inductive effect (σI-
F = 0.45, σI-CF3 = 0.38), and display similar affinity. However, the smaller fluoro substituent 
(vdW radius 1.47 Å) displays allosteric pharmacology whereas the larger trifluoromethyl 
substituent (vdW radius 2.43 Å) is a competitive antagonist. Interestingly, the 7-bromo 
analogue (12e) demonstrates a significantly greater functional affinity compared to the 
corresponding 7-trifluoromethyl (12f) and 7-chloro (12d) analogues, yet these substituents 
have comparable vdW radii. This may result from the greater degree of halogen bonding36,37 
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exhibited by bromine by virtue of its larger positive electrostatic potential compared to 
chlorine. The ensuing sigma hole has a greater potential to interact with electronegative 
atoms (such as hydroxyls in Ser, Thr and Tyr) within the orthosteric binding pocket via 
halogen bonding interactions.38 It must be noted that to further explain the trends of this data, 
additional derivatives with substituents on various positions of the THIQ core representing all 
four quadrants of the Craig plot would be informative.  
We next examined the effect of expanding the size of the heterocyclic ring of the THIQ 
scaffold, without any aromatic substitution, to tetrahydrobenzo[c]azepine (12g), which 
resulted in a 3-fold loss of functional affinity (KB = 2.57 µM) and  no significant change in 
negative allosteric cooperativity (Logαβ = -0.79 ± 0.12, Table 2). We also examined the 
effect of bioisosteric replacement of the fused benzene ring for thiophene to afford the 
tetrahydrothieno[3,2-c]pyridine (12h), which displayed no change in functional affinity (KB = 
339 µM) but significantly reduced negative allosteric cooperativity compared to 12b (Log αβ 
= -0.51 ± 0.10, Table 2). 
The strategy of ‘core hopping’ was also investigated, whereby the THIQ scaffold was 
replaced with other core substructures, (2-methoxyphenyl)piperazine (12i) and (2,3-
dichlorophenyl)piperazine (12j), which are known to be privileged scaffolds for the 
D2R.
28,39,40 The incorporated modification to (2-methoxyphenyl)piperazine (12i) resulted in 
the compound with the highest functional affinity of the series (KB = 0.26 nM), yet displayed 
competitive pharmacology with dopamine. Similarly, modification to the 1-(2,3-
dichlorophenyl)piperazine (12j) resulted in high functional affinity (KB = 1.38 nM), and also 
behaved competitively (Table 2). However, these data were best fit by Schild slope of 0.57 ± 
0.12 and a decrease in the maximal effect of dopamine was observed, both indicators of 
hemiequilibrium conditions.  
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Together, these results suggest that subtle modifications to the head group can have 
significant effects on both functional affinity and negative allosteric cooperativity. These 
observations are not surprising given we, and others, have shown that subtle changes to 
ligand-receptor interactions in the orthosteric binding site of the D2R of ligands with similar 
scaffolds can modulate affinity, subtype selectivity, efficacy and even biased 
agonism.18,30,41,42 When the THIQ head group was replaced with ‘privileged 
scaffolds’28,39,40,43,44 (12i and 12j), we observed a change from allosteric to competitive 
pharmacology accompanied by an increase in affinity. This increase in affinity is reflected by 
a comparison of the literature binding affinities of the respective head groups without 
modification where the THIQ  head group displays lower affinity (9a, D2R-KB = 2.5 µM;
20) 
than either of the privileged motifs (9i, D2R-KB = 0.137 µM;
18 9j, D2R-KB = 0.680 µM
18). 
Furthermore, the competitive rather than allosteric pharmacology of 12i and 12j is consistent 
with a bitopic mode of engagement for 1 at the D2R, whereby contacts within both the 
conserved orthosteric and putative allosteric pocket are critical for its pharmacology. Indeed 
positioning of the secondary pharmacophore within the allosteric binding site may be 
dependent on the binding orientation of the head group within the orthosteric pocket.  
The next molecular feature of 1 that we focused on was the trans-cyclohexylene spacer 
group (Table 3). We have previously shown the importance of the spacer group in that 
modification of stereochemistry around the 1,4-disubstituted cyclohexylene motif from trans 
to cis can cause a switch from negative allosteric cooperativity to competitive antagonism.20 
We sought to examine the importance of spacer configuration by installing simple flexible 
spacers with nonfunctionalized polymethylene extensions. The modification from the trans-
cyclohexylene spacer group to the 1,3-propylene spacer (18a) or a 1,4-butylene spacer (18b) 
resulted in a significant increase in functional affinity (KB = 138 nM and KB = 81 nM, 
respectively) and maintenance in the level of negative allosteric cooperativity relative to 1 
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(Table 3). Interesingly, incorporation of the 1,5-pentylene spacer (18c) displayed functional 
affinity (KB = 132 nM) no different from the 1,3-propylene spacer (18a), yet displayed 
competitive pharmacology with dopamine. However, allosteric pharmacology was restored 
for the 1,6-hexylene-containing analogue (18d) (Logαβ = -1.68 ± 0.35) and was accompanied 
by a further significant increase in functional affinity (KB = 30 nM). The use of flexible 
linkers has also been used to explore the distance between such orthosteric and allosteric sites 
or even between orthosteric sites within GPCR receptor dimers.9,11,45,46 Our findings 
demonstrate that flexibility in the spacer region is beneficial for enhancements to functional 
affinity relative to the rigid cyclohexylene spacer. This result could be expected given the 
ability for ligands to occupy two binding sites simultaneously could be more energetically 
favourable with a flexible linker.11,47-49 However, it should be noted that no such 
enhancements in binding affinity were observed. Such discrepancies between binding and 
functional affinity has been the focus of a number of recent papers.50,51 Indeed, we observed a 
similar discrepancy in a series of structurally related biased agonists at the D2R.
30 Of 
particular interest, the 1,5-pentylene analogue (18c) displays competitive antagonism, 
whereas analogues containing the 1,3-propylene (18a), 1,4-butylene (18b) and 1,6-hexylene 
(18d) spacers display negative allosteric cooperativity. Although such linkers are flexible, 
they possess a degree of conformational constraint such that the odd numbered carbon chain 
of 18c may orientate the secondary 1H-indole-2-carboxamide pharmacophore into an 
unfavourable position for interaction with the allosteric binding pocket. This is plausable 
given we have previously shown that orientation of 1 in the binding pocket requires a linear 
orientation of the allosteric moiety relative to the head group, and that a different orientation 
(i.e. from trans to cis orientation of the 1,4-cyclohexylene spacer) resulted in loss of allosteric 
pharmacology.20 Furthermore, previous studies on bitopic ligands have demonstrated a 
linker-length dependency upon the novel pharmacology conferred by engagement of both 
Page 14 of 80
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 
 
allosteric and orthosteric sites; be it a gain in affinity, subtype selectivity or biased 
agonism.9,11  
     We next examined the effect of modifying the 1H-indole-2-carboxamide tail group of 1, 
which we have previously shown to form important interactions with residues in a secondary 
binding site of the D2R,
20 and that these interactions are crucial for the determination of 
negative allosteric cooperativity (Table 4). Specifically, we have demonstrated the role of 
hydrogen bonding interactions between the indolic NH and Glu952.65 as a determinant of 
negative allosteric cooperativity and functional affinity. Therefore, we synthesized analogues 
of 1 with variations to the tail group to better examine this effect. The 1-methylindole 
analogue (25d) which, as previously described,20 can no longer act as a hydrogen bond donor, 
displayed improved functional affinity for the D2R (KB = 72 nM), yet behaved as a 
competitive antagonist. Given there is another potential hydrogen bond donating nitrogen in 
the near vicinity, we generated the N-methylated carboxamide analogue (23), which resulted 
in improved functional affinity (KB = 91 nM) as compared to 1 (KB = 776 nM), and retained 
negative allosteric cooperativity albeit reduced (Logαβ = -0.57 ± 0.10). This supported our 
hypothesis that a hydrogen bond between the indolic NH (and not the amide NH) and 
Glu952.65 is crucial for negative allosteric cooperativity.  
However, because replacement of a hydrogen with a methyl group also introduces extra bulk,  
we further investigated this hypothesis by examining other tail groups (Table 4) that cannot 
act as hydrogen bond donors yet retain similar steric properties to the lead molecule, 1. The 
benzofuran analogue (25a) displayed increased functional affinity (KB = 18 nM) relative to 1, 
yet acted as a competitive antagonist, whereas the benzoxazole (25b) (also incapable of 
hydrogen bond donation) demonstrated similar functional affinity (KB = 18 nM) to 25a, and 
was best fit by a model of competitive antagonism. However, it should be noted that in both 
cases the Schild slope obtained in this analysis was significantly less than unity. The indene 
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analogue (25c), resulting in removal of all heteroatoms in the tail group, caused a significant 
increase in functional affinity (KB = 25 nM) relative to 1 and again behaved as a competitive 
antagonist. These results support the hypothesis that maintaining the hydrogen bonding 
interaction between the receptor (most likely with the Glu2.65 highlighted as important for the 
allosteric pharmacology of 120) and the indolic NH moiety is a determining factor for 
negative allosteric pharmacology. Disturbance of this interaction has shown in all cases to 
result in both competitive antagonism and a significant increase in functional affinity relative 
to 1, confirming the results of our previous study.20  However, our data also suggests that this 
hydrogen bonding interaction may make the interaction of the head group with the orthosteric 
pocket less favourable, thus conferring a loss of affinity for such bitopic ligands. 
We subsequently explored further changes to the tail group to examine the effect of 
modifying the acidity of the indolic NH moiety, and also the lipophilicity and size of the tail 
group. The benzimidazole analogue (25e) presented a tail moiety that is theoretically a 
stronger hydrogen bond donor than indole (benzimidazole pKa = 16.4, indole pKa = 21.0)
52 
due to the anionic stabilizing effect of the second additional electronegative nitrogen atom. 
This modification displayed no significant change in functional affinity (KB = 174 nM), yet 
displayed pharmacology consistent with competitive antagonism of dopamine. This was a 
surprising finding given the previously established importance of hydrogen-bond donating 
properties on the indolic NH moiety. The 5-membered ring of the benzimidazole system is 
electron-deficient compared to its electron-rich indole counterpart of 1, and may govern the 
level of negative allostery or lack thereof when binding to the secondary binding pocket. 
Similarly, the benzimidazole NH of 25e may be in a different relative orientation compared 
to the indole NH of 1 as a result of the differing alignment of intramolecular dipoles of the 
respective molecules. This could potentially direct the benzimidazole NH opposite relative to 
the amide NH and therefore impact on hydrogen-bond donating/accepting interactions with 
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Glu952.65 in the allosteric binding site. Further experiments are required to elucidate precise 
reasons for this finding. 
Interestingly, the 7-azaindole analogue (25f) caused a significant increase in functional 
affinity (KB = 23 nM) but with maintenance of the allosteric pharmacology (Logαβ = -1.39 ± 
0.16). The chemical and physical properties of 7-azaindole are considerably different to those 
of indole53 and present multiple hydrogen-bonding opportunities, including H-bond donating 
from two different nitrogen atoms, and multiple H-bond acceptor sites.54 Given that 25f 
displays such high functional affinity whilst retaining allosteric pharmacology, it is 
reasonable to consider that the unique physical and electronic effects of 7-azaindole allows 
important hydrogen-bond donating/accepting interactions with residues in the allosteric 
binding site, including Glu952.65, which promote both high affinity and allosteric 
pharmacology.  
We then explored the pyrrole analogue (26) as a ring-deleted analogue of 1 to examine the 
biological effect of reducing lipophilicity whilst retaining the ability for hydrogen-bond 
donation, and preserving similar acidity (pyrrole-pKa = 23.0) to indole (indole-pKa = 21.0).
52 
This resulted in a significantly increased functional affinity (KB = 3 nM), yet as a competitive 
antagonist. This finding indicates that the more extensive planar aromatic structures in the 
allosteric binding pocket may also be crucial for allosteric pharmacology, which has been 
previously suggested to be important for improving selectivity of compounds for D2-like 
receptor subtypes.14,19 While it would be expected that the larger, more lipophilic indole 
moiety of 1 would confer higher functional affinity than the pyrrole moiety we observe the 
opposite pattern. This is in agreement with our previous finding that the acetamide analogue, 
N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)acetamide 
(MIPS1059),20 is a competitive antagonist with significantly higher affinity than 1. 
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Finally, we also synthesized the pyrrolidine analogues from D- (27b) and L-proline (28b). 
The most striking differences to the pyrrole analogue (26) are the introduction of a basic 
nitrogen capable of protonation at physiological pH, the lack of aromaticity and also 
planarity. We hypothesized that introduction of the basic nitrogen would (on protonation) 
result in a strong charge-reinforced hydrogen-bonding interaction with Glu952.65, thus 
maintaining allosteric pharmacology. However, in both cases of proline analogues, this 
modification resulted in competitive antagonists with a significant increase in functional 
affinity (KB = 27 nM and 46 nM, respectively). There was no significant difference between 
the D- and L-proline analogues. Given the requirement of aromaticity for allosteric 
pharmacology previously discussed for the pyrrole analogue (26), it is reasonable to consider 
that the loss of allosteric pharmacology observed for the proline analogues (27b and 28b) is 
also related to a lack of aromaticity, and reaffirms the importance of size and lipophilicity in 
the allosteric pocket. In summary, orthosteric and allosteric pharmacology is most sensitive to 
changes to the tail moiety, where modifications that disrupted its hydrogen-bond donor 
ability, or its size and lipophilicity, generally resulted in loss of allostery, and a concomitant 
gain in affinity. However, fine tuning of the tail group was capable of producing compounds 
with high functional affinity and maintenance of negative allosteric pharmacology, for 
example the 7-azaindole analogue (25f). 
It must be acknowledged that, while our experimental approach allowed determination of 
parameters of both affinity and negative cooperativity for ligands that display allosteric 
pharmacology, we cannot exclude the possibility that compounds that appear to behave 
competitively with dopamine and [3H]raclopride, may instead display very high negative 
cooperativity. Such high negative cooperativity would be indistinguishable from competitive 
antagonism. Thus, such compounds would not display the partial antagonism of the D2R of 
ligands conferred by modest negative cooperativity that, in theory, may be beneficial for the 
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treatment of the positive symptoms of schizophrenia. Furthermore, it should be noted that 1 
has the key attributes of a D2R competitive ligand. In general the structural modifications that 
appear to result in competitive behaviour can be reconciled with our previously described 
mechanism of action for 1 whereby the interaction of the indole moiety of 1 with a secondary 
pocket between TM2 and TM7 confers allosteric pharmacology. 
Finally, we have previously provided evidence that 1 acts as a negative allosteric modulator 
at a D2R dimer. This SAR study has given insight into the structural determinants of the 
allosteric action of 1 at the D2R and is consistent with the bitopic mode of interaction 
proposed in our first study. However, it was beyond the scope of this study to confirm the 
action of such novel ligands at a D2R dimer. Future studies will focus on gaining further 
insight into the action of these novel THIQ analogues at D2R dimers. 
 
Conclusions 
We have previously provided evidence that 1 binds in a bitopic manner at one protomer of 
a D2R dimer and modulates the binding of dopamine at a second protomer. Furthermore, we 
discovered that a hydrogen bond between the indolic NH of 1 and Glu952.65 within the 
secondary pocket is a key ligand-receptor interaction for the allosteric action of 1. In this 
study we designed and synthesized analogues of 1 to determine the key ligand features 
required for allosteric pharmacology, and successfully identified compounds with high 
affinity and a spectrum of negative cooperativity at the D2R. The results of this SAR 
approach further validates the bitopic mode of action for 1, whereby subtle structural 
modifications to any component of the scaffold can have significant consequences on the 
pharmacology of the resulting compound. We focused on synthetic analogues of three main 
portions of the molecule: the THIQ head group; the trans-1,4-cyclohexylene spacer group; 
and the 1H-indole-2-carboxamide tail group. The most sensitive region to chemical 
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modifications was the tail group, where any disturbance of the indole NH hydrogen-bond 
donor ability, or size and lipophilicity, resulted in a change from allosteric to apparent 
competitive pharmacology. The THIQ head group is crucial for maintaining allosteric 
pharmacology, with the requirement of a ‘small’ substituent in the 7-position. When the 
THIQ head group was replaced with higher affinity ‘privileged scaffolds’ we observed a 
change from allosteric to competitive pharmacology. We hypothesize that smaller, lower-
affinity orthosteric head groups are more favourable for allosteric pharmacology because they 
allow correct orientation of the tail group within the secondary binding pocket. We also 
discovered an intriguing relationship between alkyl chain spacer length and allosteric 
pharmacology, in which the alternating length of the alkyl spacer may change the orientation 
of the secondary pharmacophore causing a switch from allosteric to competitive 
pharmacology. Replacement of the trans-1,4-cyclohexylene spacer group with a linear 1,4-
butylene or 1,6-hexylene spacer group conferred an increase in functional affinity wile 
maintaining allosteric pharmacology. Finally, replacement of the indole moiety with a 7-
azaindole, which presents multiple hydrogen-bond donating and accepting moities, conferred 
a 30-fold increase in affinity with maintenance of negative cooperativity with dopamine. The 
findings of this study provide further insight as to the bitopic binding mode of 1 at the D2R, 
and present future opportunities for drug design of bitopic and allosteric molecules for the 
D2R.  
 
 
Experimental  
General Experimental 
All reagents were purchased from Accela ChemBio, Alfa Aesar, AK Scientific, AstaTech, 
ChemImpex, CombiBlocks, Otava Chemicals or Sigma-Aldrich and used without 
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purification. GR grade NH4OH solution (28% aqueous solution), and LR grade MeOH, 
EtOAc, CHCl3, DCM, Pet. Spirits and MeCN were purchased from Merck and used without 
further purification. Dry DMF was obtained from an MBraun MB-SPS-800. Davisil® silica 
gel (40-63µm), for flash column chromatography was supplied by Grace Davison Discovery 
Sciences (Victoria, Australia) and deuterated solvents were purchased from Cambridge 
Isotope Laboratories, Inc. (USA, distributed by Novachem PTY. Ltd, Victoria, Australia). 
All organic extracts collected after aqueous work-up procedures were dried over anhydrous 
Na2SO4 before gravity filtering and concentration in vacuo at ≤ 40°C (water bath 
temperature).  Purification using preparative layer chromatography (PLC) was carried out on 
Analtech preparative TLC plates (200 mm x 200 mm x 2 mm). 
 All 1H NMR and 13C NMR spectra (DEPTQ) were recorded on a Bruker Avance III 400 
Ultrashield Plus spectrometer at 400.13 and 100.62 MHz respectively. Results were recorded 
as follows: chemical shift values are expressed as δ units acquired in CDCl3, or d6-DMSO 
when specified, with tetramethylsilane (0.00 ppm) as reference for 1H NMR (residual solvent 
peak as reference for 13C NMR);55 multiplicity (singlet (s), doublet (d), triplet (t), pentet (p), 
quartet (q), broad (br), multiplet (m), doublet of doublets (dd), doublet of triplets (dt), triplet 
of triplets (tt)); coupling constants (J) in Hertz; and, integration. Thin-layer chromatography 
was conducted on 0.2 mm plates using Merck silica gel 60 F254. Flash column 
chromatography was performed using Merck Silica Gel 60, 230-400 mesh ASTM, or using 
automated CombiFlash® Rf 200 with specified solvents. High resolution mass spectra 
(HRMS) were obtained on a Waters LCT Premier XE (TOF) using electrospray ionization 
(ESI) at a cone voltage of 50 V.  
LCMS were run using one of two systems to verify reaction outcome and purity. System A 
was the default unless otherwise stated. System A - an Agilent 6100 Series Single Quad 
coupled to an Agilent 1200 Series HPLC using the following buffers; buffer A: 0.1% formic 
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acid in H2O; buffer B: 0.1% formic acid in MeCN.  The following gradient was used with a 
Phenomenex Luna 3 µm C8(2) 15 x 4.6 mm column, and a flow rate of 0.5 mL/min and total 
run time of 12 min; 0–4 min 95% buffer A and 5% buffer B, 4–7 min 0% buffer A and 100% 
buffer B, 7–12 min 95% buffer A and 5% buffer B. Mass spectra were acquired in positive 
and negative ion mode with a scan range of 0–1000 m/z at 5V. UV detection was carried out 
at 254 nm. System B - an Agilent 6120 Series Single Quad coupled to an Agilent 1260 Series 
HPLC. The following buffers were used; buffer A: 0.1% formic acid in H2O; buffer B: 0.1% 
formic acid in MeCN.  The following gradient was used with a Poroshell 120 EC-C18 50 × 
3.0 mm 2.7 µm column, and a flow rate of 0.5 mL/min and total run time of 5 min; 0–1 min 
95% buffer A and 5% buffer B, from 1-2.5 min up to 0% buffer A and 100% buffer B, held at 
this composition until 3.8 min, 3.8–4 min 95% buffer A and 5% buffer B, held until 5 min at 
this composition.  Mass spectra were acquired in positive and negative ion mode with a scan 
range of 100–1000 m/z. UV detection was carried out at 214 and 254 nm. All retention times 
(tR) are quoted in min. Analytical reverse-phase HPLC was performed on a Waters HPLC 
system coupled directly to a photodiode array detector and fitted with a Phenomenex® Luna 
C8 (2) 100 Å column (150 mm × 4.6 mm, 5 µm) using a binary solvent system; solvent A: 
0.1% TFA/H2O; solvent B: 0.1% TFA/80% CH3CN/H2O. Gradient elution was achieved 
using 100% solvent A to 100% solvent B over 20 min at a flow rate of 1 mL/min. All 
compounds subjected to biological testing were found to be >95 % pure by HPLC at two 
wavelengths (λ = 254 and 214 nm). 
 
General Procedure A (Reductive alkylation with tert-butyl (trans-4-(2-
oxoethyl)cyclohexyl)carbamate): The secondary amine (1 eq.) and tert-butyl (trans-4-(2-
oxoethyl)cyclohexyl)carbamate30 (8, 1 eq.) were taken up in 1,2-DCE (10 mL). NaBH(OAc)3 
(1.5 eq) was added to the stirred solution at RT under nitrogen. After 16–24 h LCMS 
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confirmed reaction completion. The mixture was diluted with DCM (15 mL), washed with 1 
M K2CO3 solution (3 × 20 mL), brine (15 mL), then dried and concentrated in vacuo. The 
crude material was purified by flash column chromatography to give the title compound. 
General Procedure B (N-Boc deprotection): The N-Boc protected amine was taken up in 
a mixture of DCM (5 mL) and TFA (1 mL) at RT. After 16 h stirring, the solution was 
diluted with DCM (20 mL) and water (5 mL), followed by dropwise addition of NH4OH 
solution (approx. 3 mL or until pH 10). The product was extracted with further DCM (2 × 15 
mL), and the combined organic extracts washed with brine (20 mL), dried over Na2SO4 and 
concentrated in vacuo. 
General Procedure C (N-Boc protection): To a stirred mixture of the amine (1.2 eq.) in 
DCM (50 mL/g amine) at RT, was slowly added NEt3 (1.2 eq.), followed by dropwise 
addition of a solution of Boc2O (1 eq.) in DCM (5 mL/g Boc2O). After 1 – 24 h, the reaction 
was washed with 1 M KHSO4 (3 × 30 mL), brine, dried and concentrated in vacuo. 
General Procedure D (Activation of alcohols to corresponding methanesulfonate 
esters): To a solution of the alcohol (1 eq.) in DCM (20 mL) was added NEt3 (2 eq.). After 5 
min, a solution of methanesulfonyl chloride (1.2 eq.) in DCM (5 mL) was added dropwise. 
After 16 h stirring at RT, the solution was washed with 1 M NaOH (20 mL), 1 M KHSO4 (20 
mL), brine, then dried and concentrated in vacuo. 
General Procedure E (HCTU-mediated amide coupling): The amine (1 eq.) was taken 
in dry DMF (5-10 mL), and under N2 at RT was added the carboxylic acid (1.2 eq.) followed 
by HCTU (1.5 eq.) and DIPEA (5 eq.). After 16 h, the solution was concentrated in vacuo, 
then 2 M NaHCO3 (20 mL) was added, and the product extracted with EtOAc (20 mL). The 
organic layer was then washed with 2 M NaHCO3 (2 × 20 mL), brine (20 mL), then dried and 
concentrated in vacuo. The product was then purified by flash column chromatography in 
specified conditions. 
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2,3,4,5-Tetrahydro-1H-benzo[c]azepin-1-one (3).
31 1-Tetralone (2) (1.00 g, 6.84 mmol) 
was taken up in conc. HCl (12 mL) with ice cooling to 0 °C, and sodium azide (889 mg, 13.7 
mmol) was slowly added portionwise to maintain 0 °C. After complete addition, the mixture 
was warmed to RT, then heated at 50 °C for 16 h. The mixture was then poured into ice-cold 
water (15 mL), and made alkaline with slow addition of 1 M K2CO3 to pH 10. The product 
was then extracted with DCM (3 × 30 mL), and the organic extracts were combined, dried 
and concentrated in vacuo. The product was purified by flash column chromatography 
(EtOAc) to give pale yellow needles (675 mg, 61%, lit.31 52%). 1H NMR δ 7.71 (dd, J = 
7.5/1.4 Hz, 1H), 7.51 (s, 1H), 7.40 (td, J = 7.4/1.6 Hz, 1H), 7.34 (td, J = 7.5/1.4 Hz, 1H), 7.19 
(dd, J = 7.4/0.8 Hz, 1H), 3.13 (q, J = 6.5 Hz, 2H), 2.87 (t, J = 7.1 Hz, 2H), 2.02 (p, J = 6.8 
Hz, 2H). 13C NMR δ 174.4 (C), 138.5 (C), 135.2 (C), 131.3 (CH), 128.74 (CH), 128.70 (CH), 
127.0 (CH), 39.6 (CH2), 30.7 (CH2), 30.4 (CH2). 
2,3,4,5-Tetrahydro-1H-benzo[c]azepine (4).
56 Lithium aluminium hydride (177 mg, 4.65 
mmol) was taken in dry THF (10 mL), and to the stirred solution under N2 at 0 °C was slowly 
added a solution of 2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one (3) (250 mg, 1.55 mmol) in 
dry THF (5 mL). The solution was stirred at RT for 30 min, then heated to reflux. After 16 h, 
the mixture was cooled on ice, and water (15 mL) was slowly added. The solids were filtered 
through a plug of Celite, and then washed with Et2O (30 mL). The product was then further 
extracted with Et2O (2 × 20 mL), and the combined extracts were dried and concentrated in 
vacuo to reveal the title compound as a clear oil (197 mg, 86%, lit.56 60%) which required no 
further purification. 1H NMR δ 7.17 – 7.07 (m, 4H), 3.92 (s, 2H), 3.24 – 3.15 (m, 2H), 2.98 – 
2.89 (m, 2H), 1.76 – 1.66 (m, 2H), 1.41 (s, 1H). 13C NMR δ 143.1 (C), 143.0 (C), 129.3 
(CH), 128.4 (CH), 127.1 (CH), 126.1 (CH), 55.3 (CH2), 53.8 (CH2), 36.3 (CH2), 31.1 (CH2). 
tert-Butyl ((trans)-4-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)carbamate 
(10b). Following General Procedure A using 1,2,3,4-tetrahydroisoquinoline (9b) (82.8 mg, 
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622 µmol). Flash column chromatography (EtOAc) gave the title compound as a white solid 
(190 mg, 85% yield). 1H NMR δ 7.16 – 7.05 (m, 3H), 7.04 – 6.97 (m, 1H), 4.39 (br s, 1H), 
3.60 (s, 2H), 3.38 (br s, 1H), 2.89 (t, J = 5.9 Hz, 2H), 2.71 (t, J = 5.9 Hz, 2H), 2.53 – 2.50 (m, 
2H), 2.02 – 1.94 (m, 2H), 1.84 – 1.72 (m, 2H), 1.55 – 1.45 (m, 2H), 1.44 (s, 9H), 1.33 – 1.20 
(m, 1H), 1.13 – 0.97 (m, 4H). 13C NMR δ 155.4 (C), 134.9 (C), 134.4 (C), 128.7 (CH), 126.7 
(CH), 126.2 (CH), 125.7 (CH), 79.1 (C), 56.4 (CH2), 56.3 (CH2), 51.1 (CH2), 50.0 (CH), 35.4 
(CH), 34.3 (CH2), 33.6 (CH2), 32.1 (CH2), 29.2 (CH2), 28.6 (CH3). HRMS (m/z): [MH]
+ 
calcd. for C22H34N2O2, 359.2693; found 359.2711. 
tert-Butyl (trans-4-(2-(7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl) 
carbamate (10c). Following General Procedure A using 7-fluoro-1,2,3,4-
tetrahydroisoquinoline hydrochloride (9c) (231 mg, 1.23 mmol) and DIPEA (429 µL, 2.46 
mmol). Flash column chromatography (EtOAc:pet. spirits, 4:1, v/v) gave the title compound 
as a pale yellow solid (195 mg, 46%). 1H NMR δ 7.03 (dd, J = 8.4/5.8 Hz, 1H), 6.81 (td, J = 
8.5/2.6 Hz, 1H), 6.71 (dd, J = 9.4/2.5 Hz, 1H), 4.46 (s, 1H), 3.56 (s, 2H), 3.43 – 3.30 (m, 1H), 
2.84 (t, J = 5.7 Hz, 2H), 2.69 (t, J = 5.9 Hz, 2H), 2.53 – 2.46 (m, 2H), 2.05 – 1.93 (m, 2H), 
1.84 – 1.75 (m, 2H), 1.54 – 1.41 (m, 11H), 1.33 – 1.21 (m, 1H), 1.14 – 0.98 (m, 4H). 13C 
NMR δ 162.2 (C), 159.8 (C), 155.3 (C), 136.8 (C, d, JCF = 7.1 Hz), 130.0 (CH, d, JCF = 7.9 
Hz), 129.9 (C, d, JCF = 2.8 Hz), 113.2 (CH, d, JCF = 21.3 Hz), 112.9 (CH, d, JCF = 21.2 Hz), 
79.0 (C), 56.17 (CH2), 56.15 (CH2), 51.0 (CH2), 49.9 (CH), 35.3 (CH), 34.2 (CH2), 33.5 
(CH2), 32.0 (CH2), 28.5 (CH3), 28.4 (CH2). HRMS (m/z): [MH]
+ calcd. for C22H33FN2O2, 
377.2599; found 377.2604. 
tert-Butyl (trans-4-(2-(7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl) 
carbamate (10d). Following General Procedure A using 7-chloro-1,2,3,4-
tetrahydroisoquinoline (9d) (160 mg, 957 µmol). Purification by flash column 
chromatography (EtOAc:Pet. spirits, 2:1, v/v) gave the title compound as a pale yellow oil 
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(104 mg, 30%). 1H NMR δ 7.11 (dd, J = 8.2/2.1 Hz, 1H), 7.06 – 7.00 (m, 2H), 4.37 (s, 1H), 
3.67 (s, 2H), 3.39 (d, J = 13.4 Hz, 1H), 2.91 – 2.76 (m, 4H), 2.66 – 2.55 (m, 2H), 2.03 – 1.95 
(m, 2H), 1.83 – 1.75 (m, 2H), 1.52 (dd, J = 15.4/6.9 Hz, 2H), 1.44 (s, 9H), 1.31 – 1.26 (m, 
1H), 1.10 – 1.01 (m, 4H). 13C NMR δ 155.3 (C), 136.8 (C), 132.9 (C), 131.1 (C), 130.0 (CH), 
126.5 (CH), 126.3 (CH), 79.1 (C), 56.2 (CH2), 55.9 (CH2), 50.8 (CH2), 50.0 (CH), 35.3 (CH), 
34.2 (CH2), 33.5 (CH2), 32.1 (CH2), 28.6 (CH2), 28.5 (CH3). HRMS (m/z): [MH]
+ calcd. for 
C22H33ClN2O2, 393.2303; found 393.2306. 
tert-Butyl (trans-4-(2-(7-bromo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl) 
carbamate (10e). Following General Procedure A using 7-bromo-1,2,3,4-
tetrahydroisoquinoline (9e) (203 mg, 957 µmol). Flash column chromatography (EtOAc) 
gave the title compound as a pale yellow oil (110 mg, 29%). 1H NMR δ 7.23 (dd, J = 8.1/2.0 
Hz, 1H), 7.17 – 7.14 (m, 1H), 6.96 (d, J = 8.2 Hz, 1H), 4.37 (s, 1H), 3.56 (s, 2H), 3.37 (s, 
1H), 2.82 (t, J = 5.9 Hz, 2H), 2.69 (t, J = 5.9 Hz, 2H), 2.56 – 2.44 (m, 2H), 2.04 – 1.95 (m, 
2H), 1.84 – 1.73 (m, 2H), 1.53 – 1.42 (m, 11H), 1.29 – 1.22 (m, 1H), 1.12 – 0.97 (m, 4H). 13C 
NMR δ 155.4 (C), 137.3 (C), 133.6 (C), 130.4 (CH), 129.5 (CH), 129.3 (CH), 119.2 (C), 79.1 
(C), 56.2 (CH2), 55.9 (CH2), 50.8 (CH2), 50.0 (CH), 35.4 (CH), 34.3 (CH2), 33.6 (CH2), 32.1 
(CH2), 28.7 (CH2), 28.6 (CH3). HRMS (m/z): [MH]
+ calcd. for C22H33BrN2O2, 437.1798; 
found 437.1803. 
tert-Butyl (trans-4-(2-(7-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl) 
cyclohexyl)carbamate (10f). Following General Procedure A using 7-(trifluoromethyl)-
1,2,3,4-tetrahydroisoquinoline hydrochloride (9f) (227 mg, 957 µmol) and DIPEA (333 µL, 
1.91 mmol). Flash column chromatography (EtOAc:pet. spirits, 1:1, v/v) gave the title 
compound as a pale yellow solid (125 mg, 34%). 1H NMR δ 7.36 (d, J = 8.0 Hz, 1H), 7.28 (s, 
1H), 7.19 (d, J = 8.0 Hz, 1H), 4.37 (s, 1H), 3.64 (s, 2H), 3.38 (s, 1H), 2.94 (t, J = 5.7 Hz, 2H), 
2.73 (t, J = 5.9 Hz, 2H), 2.59 – 2.48 (m, 2H), 1.98 (s, 2H), 1.85 – 1.75 (m, 2H), 1.54 – 1.42 
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(m, 11H), 1.33 – 1.26 (m, 1H), 1.14 – 0.96 (m, 4H). 13C NMR δ 155.4 (C), 138.8 (C), 135.8 
(C), 129.2 (CH), 128.1 (C, q, JCF = 32.2 Hz), 124.4 (C, q, JCF = 271.8 Hz), 123.6 (CH, q, JCF 
= 3.8 Hz), 122.9 (CH, q, JCF = 3.7 Hz), 79.1 (C), 56.3 (CH2), 56.1 (CH2), 50.7 (CH2), 50.0 
(CH), 35.4 (CH), 34.2 (CH2), 33.5 (CH2), 32.1 (CH2), 29.3 (CH2), 28.6 (CH3). HRMS (m/z): 
[MH]+ calcd. for C23H33F3N2O2, 427.2567; found 427.2586. 
tert-Butyl (trans-4-(2-(4,5-dihydro-1H-benzo[c]azepin-2(3H)-yl)ethyl)cyclohexyl) 
carbamate (10g). Following General Procedure A using 2,3,4,5-tetrahydro-1H-
benzo[c]azepine (9g) (121 mg, 820 µmol). Purification by flash column chromatography 
(EtOAc:MeOH, 90:10, v/v) gave the title compound as a pale yellow oil (62 mg, 22%). 1H 
NMR δ 7.21 – 7.06 (m, 4H), 4.35 (s, 1H), 3.90 (s, 2H), 3.34 (s, 1H), 3.17 – 3.06 (m, 2H), 
2.95 – 2.84 (m, 2H), 2.40 – 2.31 (m, 2H), 1.99 – 1.91 (m, 2H), 1.75 – 1.65 (m, 4H), 1.47 – 
1.35 (m, 11H), 1.22 – 1.11 (m, 1H), 1.09 – 0.90 (m, 4H). 13C NMR δ 155.4 (C), 143.0 (C), 
138.9 (C), 130.0 (CH), 129.0 (CH), 127.4 (CH), 126.1 (CH), 79.2 (C), 59.3 (CH2), 59.0 
(CH2), 50.8 (CH2), 50.0 (CH), 36.2 (CH2), 35.2 (CH), 34.3 (CH2), 33.5 (CH2), 32.1 (CH2), 
28.6 (CH3), 24.9 (CH2). HRMS (m/z): [MH]
+ calcd. for C23H36N2O2, 373.2850; found 
373.2853. 
tert-Butyl ((trans)-4-(2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethyl)cyclohexyl) 
carbamate (10h). Following General Procedure A using 4,5,6,7-tetrahydrothieno[3,2-
c]pyridine hydrochloride (9h) (160 mg, 912 µmol) and DIPEA (289 µL, 1.66 mmol). 
Purification by flash column chromatography (EtOAc:Pet. spirits, 1:1, v/v) gave the title 
compound as a white solid (42 mg, 14%). 1H NMR δ 7.06 (d, J = 5.1 Hz, 1H), 6.71 (d, J = 
5.1 Hz, 1H), 4.38 (s, 1H), 3.53 (s, 2H), 3.36 (s, 1H), 2.88 (t, J = 5.5 Hz, 2H), 2.77 (t, J = 5.7 
Hz, 2H), 2.57 – 2.50 (m, 2H), 2.04 – 1.94 (m, 2H), 1.82 – 1.73 (m, 2H), 1.52 – 1.42 (m, 
11H), 1.30 – 1.24 (m, 1H), 1.15 – 0.99 (m, 4H). 13C NMR δ 155.4 (C), 134.0 (C), 133.6 (C), 
125.4 (CH), 122.7 (CH), 79.1 (C), 55.9 (CH2), 53.3 (CH2), 51.1 (CH2), 50.0 (CH), 35.4 (CH), 
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34.5 (CH2), 33.6 (CH2), 32.1 (CH2), 28.6 (CH3), 25.6 (CH2). HRMS (m/z): [MH]
+ calcd. for 
C20H32N2O2S, 365.2257; found 365.2274. 
tert-Butyl (trans-4-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)cyclohexyl)carbamate 
(10i). Following General Procedure A using 1-(2-methoxyphenyl)piperazine hydrochloride 
(9i) (284 mg, 1.24 mmol, 2 eq) and DIPEA (0.237 mL, 1.36 mmol, 2.2 eq). Purification by 
flash column chromatography (MeOH/DCM 0:100 to 5:95) gave the title compound as a 
white solid (235 mg, 91%). 1H NMR δ 7.00 (ddd, J = 7.9/7.1/2.2 Hz, 1H), 6.95 (dd, J = 
7.9/2.2 Hz, 1H), 6.93 – 6.90 (m, 1H), 6.86 (dd, J = 8.0/1.1 Hz, 1H), 4.48 – 4.20 (m, 1H), 3.86 
(s, 3H), 3.50 – 2.95 (m, 5H), 2.94 – 2.25 (m, 6H), 2.11 – 1.89 (m, 2H), 1.88 – 1.68 (m, 2H), 
1.67 – 1.34 (m, 11H), 1.33 – 1.16 (m, 1H), 1.16 – 0.94 (m, 4H). 13C NMR δ 159.1 (C), 152.4 
(C), 139.7 (C), 123.3 (CH), 121.2 (CH), 118.5 (CH), 111.3 (CH), 79.2 (C), 56.8 (CH2), 55.5 
(CH3), 53.5 (CH2), 53.5 (CH2), 50.0 (CH), 35.6 (CH), 34.1 (CH2), 33.5 (CH2), 32.1 (CH2), 
28.6 (CH3). m/z MS (TOF ES
+) C24H40N3O3 [MH]
+ calculated 418.3; found 418.4. LCMS tR: 
3.21 min (system B). 
tert-Butyl ((trans)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl) 
carbamate (10j). Following General Procedure A using 2,3-dichloropiperazine 
hydrochloride (9j) (332 mg, 1.24 mmol, 2 eq) and DIPEA (0.237 mL, 1.36 mmol, 2.2 eq). 
Purification by flash column chromatography (MeOH/DCM 0:100 to 5:95) gave the title 
compound as a white solid (258 mg, 91%). 1H NMR δ 7.23 – 7.09 (m, 2H), 6.97 (dd, J = 
7.2/2.4 Hz, 1H), 4.53 – 4.13 (m, 1H), 3.54 – 2.24 (m, 11H), 2.11 – 1.90 (m, 2H), 1.90 – 1.69 
(m, 2H), 1.70 – 1.36 (m, 11H), 1.36 – 1.17 (m, 1H), 1.18 – 0.92 (m, 4H). 13C NMR δ 155.4 
(C), 147.2 (C), 134.2 (C), 127.7 (CH), 125.1 (CH), 124.5 (CH), 118.9 (CH), 79.0 (C), 56.6 
(CH2), 53.3 (CH2), 53.2 (CH2), 49.9 (CH), 35.5 (CH), 34.5 (CH2), 33.49 (CH2), 32.1 (CH2), 
28.6 (CH3). m/z MS (TOF ES
+) C23H36Cl2N3O2 [MH]
+ calculated 456.2; found 456.3; LCMS 
tR: 3.55 min (system B). 
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(trans)-4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine dihydrochloride 
(11b). Following General Procedure B using tert-butyl ((trans)-4-(2-(3,4-dihydroisoquinolin-
2(1H)-yl)ethyl)cyclohexyl)carbamate (10b), followed by addition of 1 M HCl in Et2O. The 
product was collected by filtration as a white solid (74 mg, 80%). 1H NMR (D2O) δ 7.64 – 
7.54 (m, 3H), 7.51 – 7.49 (m, 1H), 4.84 – 4.79 (m, 1H), 4.54 (d, J = 15.5 Hz, 1H), 4.07 – 3.96 
(m, 1H), 3.65 – 3.26 (m, 6H), 2.27 (d, J = 10.7 Hz, 2H), 2.11 (d, J = 11.8 Hz, 2H), 1.99 (dt, J 
= 11.0/5.6 Hz, 2H), 1.70 – 1.55 (m, 3H), 1.45 – 1.26 (m, 2H). 13C NMR (D2O) δ 132.1 (C), 
130.0 (CH), 129.6 (CH), 128.8 (C), 128.4 (CH), 128.0 (CH), 55.3 (CH2), 53.6 (CH2), 50.8 
(CH), 50.7 (CH2), 34.6 (CH), 31.01 (CH2), 30.96 (CH2), 26.1 (CH2). 
trans-4-(2-(7-Fluoro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine (11c).  
Following General Procedure B using tert-butyl (trans-4-(2-(7-fluoro-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)carbamate (10c) gave the title compound as a 
yellow oil (108 mg, 97%). 1H NMR δ 7.03 (dd, J = 8.4/5.8 Hz, 1H), 6.81 (dd, J = 8.5/2.7 Hz, 
1H), 6.71 (dd, J = 9.5/2.6 Hz, 1H), 3.58 (s, 2H), 2.84 (t, J = 5.8 Hz, 2H), 2.70 (t, J = 5.9 Hz, 
2H), 2.64 – 2.56 (m, 1H), 2.54 – 2.47 (m, 2H), 1.90 – 1.82 (m, 2H), 1.82 – 1.73 (m, 2H), 1.52 
– 1.37 (m, 4H), 1.31 – 1.22 (m, 1H), 1.13 – 0.94 (m, 4H). 13C NMR δ 162.2 (C), 159.8 (C), 
136.9 (CH, d, JCF = 7.1 Hz), 130.1 (C, d, JCF = 7.9 Hz), 113.3 (CH, d, JCF = 21.3 Hz), 113.0 
(CH, d, JCF = 21.2 Hz), 56.4 (CH2), 56.3 (CH2, d, JCF = 1.8 Hz), 51.1 (CH2), 50.9 (CH), 36.8 
(CH2), 35.6 (CH), 34.4 (CH2), 32.3 (CH2), 28.5 (CH2). 
trans-4-(2-(7-Chloro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine (11d). 
Following General Procedure B using tert-butyl (trans-4-(2-(7-chloro-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)carbamate (10d) gave the title compound as a 
yellow oil (62 mg, 85%). 1H NMR δ 7.08 (dd, J = 8.2/2.1 Hz, 1H), 7.04 – 6.97 (m, 2H), 3.56 
(s, 2H), 2.84 (t, J = 5.9 Hz, 2H), 2.69 (t, J = 5.9 Hz, 2H), 2.65 – 2.54 (m, 1H), 2.53 – 2.47 (m, 
2H), 1.89 – 1.81 (m, 2H), 1.81 – 1.73 (m, 2H), 1.71 – 1.52 (br s, 2H), 1.51 – 1.44 (m, 2H), 
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1.29 – 1.22 (m, 1H), 1.05 (m, 4H). 13C NMR δ 136.8 (C), 133.0 (C), 131.1 (C), 130.0 (CH), 
126.5 (CH), 126.3 (CH), 56.3 (CH2), 56.0 (CH2), 50.9 (CH2), 50.0 (CH), 36.7 (CH2), 35.5 
(CH), 34.4 (CH2), 32.3 (CH2), 28.6 (CH2). 
trans-4-(2-(7-Bromo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine (11e). 
Following General Procedure B using tert-butyl (trans-4-(2-(7-bromo-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)carbamate (10e) gave the title compound as a 
yellow oil (73 mg, 99%). 1H NMR δ 7.22 (dd, J = 8.1/2.0 Hz, 1H), 7.17 – 7.13 (m, 1H), 6.95 
(d, J = 8.2 Hz, 1H), 3.56 (s, 2H), 2.82 (t, J = 5.8 Hz, 2H), 2.74 – 2.68 (m, 2H), 2.63 – 2.55 
(m, 1H), 2.56 – 2.45 (m, 2H), 1.94 – 1.73 (m, 6H), 1.53 – 1.40 (m, 2H), 1.29 – 1.22 (m, 1H), 
1.15 – 0.93 (m, 4H). 13C NMR δ 137.3 (C), 133.5 (C), 130.4 (CH), 129.5 (CH), 129.2 (CH), 
119.1 (C), 56.3 (CH2), 55.8 (CH2), 50.9 (CH), 50.8 (CH2), 36.6 (CH2), 35.5 (CH), 34.4 
(CH2), 32.2 (CH2), 28.7 (CH2). 
trans-4-(2-(7-(Trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl) 
cyclohexanamine (11f). Following General Procedure B using tert-butyl (trans-4-(2-(7-
(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)carbamate (10f) gave the 
title compound as a yellow oil (74 mg, 81%). 1H NMR δ 7.35 (d, J = 8.0 Hz, 1H), 7.28 (s, J = 
2.5 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 3.63 (s, 2H), 2.93 (t, J = 5.8 Hz, 2H), 2.73 (t, J = 5.9 
Hz, 2H), 2.64 – 2.50 (m, 3H), 1.91 – 1.81 (m, 2H), 1.81 – 1.71 (m, 2H), 1.53 – 1.44 (m, 2H), 
1.44 – 1.32 (m, 2H), 1.31 – 1.21 (m, 1H), 1.13 – 0.95 (m, 4H). 13C NMR δ 138.7 (C), 135.8 
(C), 129.1 (CH), 128.0 (C, q, JCF = 32.1 Hz), 124.2 (C, q, JCF = 224 Hz), 123.6 (CH, q, JCF = 
3.8 Hz), 122.8 (CH, q, JCF = 3.7 Hz), 56.4 (CH2), 56.1 (CH2), 50.9 (CH), 50.7 (CH2), 36.8 
(CH2), 35.5 (CH), 34.4 (CH2), 32.3 (CH2), 29.2 (CH2). 
trans-4-(2-(4,5-Dihydro-1H-benzo[c]azepin-2(3H)-yl)ethyl)cyclohexanamine (11g). 
Following General Procedure B using tert-butyl (trans-4-(2-(4,5-dihydro-1H-benzo[c]azepin-
2(3H)-yl)ethyl)cyclohexyl)carbamate (10g) gave the title compound as a yellow oil (44 mg, 
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99%). 1H NMR δ 7.17 – 7.07 (m, 4H), 3.88 (s, 2H), 3.15 – 3.06 (m, 2H), 2.93 – 2.85 (m, 2H), 
2.56 (tt, J = 10.8/3.8 Hz, 1H), 2.39 – 2.32 (m, 2H), 1.81 (dd, J = 13.9/2.0 Hz, 2H), 1.76 – 
1.65 (m, 4H), 1.49 – 1.22 (m, 4H), 1.21 – 1.07 (m, 1H), 1.09 – 0.87 (m, 4H). 13C NMR δ 
143.0 (C), 139.4 (C), 129.8 (CH), 128.9 (CH), 127.2 (CH), 125.9 (CH), 59.5 (CH2), 59.2 
(CH2), 51.2 (CH2), 50.9 (CH), 36.9 (CH2), 36.3 (CH2), 35.4 (CH), 34.7 (CH2), 32.3 (CH2), 
25.1 (CH2). 
trans-4-(2-(6,7-Dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethyl)cyclohexanamine (11h). 
Following General Procedure B using tert-butyl ((trans)-4-(2-(6,7-dihydrothieno[3,2-
c]pyridin-5(4H)-yl)ethyl)cyclohexyl)carbamate (10h) gave the title compound as a yellow oil 
(40 mg, 98%). 1H NMR δ 7.06 (d, J = 5.1 Hz, 1H), 6.72 (d, J = 5.1 Hz, 1H), 3.54 (t, J = 1.5 
Hz, 2H), 2.89 (t, J = 5.6 Hz, 2H), 2.77 (t, J = 5.7 Hz, 2H), 2.64 – 2.51 (m, 3H), 1.90 – 1.81 
(m, 2H), 1.81 – 1.72 (m, 2H), 1.52 – 1.44 (m, 2H), 1.39 – 1.26 (m, 3H), 1.14 – 0.95 (m, 4H). 
13C NMR δ 134.1 (C), 133.6 (C), 125.4 (CH), 122.7 (CH), 56.0 (CH2), 53.4 (CH2), 51.2 
(CH2), 50.9 (CH), 36.9 (CH2), 35.6 (CH), 34.7 (CH2), 32.3 (CH2), 25.6 (CH2). 
(trans)-4-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)cyclohexan-1-amine 
trihydrochloride (11i). tert-Butyl (trans-4-(2-(4-(2-methoxyphenyl)piperazin-1-
yl)ethyl)cyclohexyl)carbamate (10i) (215 mg, 0.51 mmol) was dissolved in MeOH (10 mL) 
at room temperature, before adding 4 M HCl/1,4-dioxane (5 mL). The mixture was stirred at 
room temperature for 3 hours, before concentrating under reduced pressure to give 228 mg of 
white solid (quantitative yield). 1H NMR (d6-DMSO) δ 11.09 (s, 1H), 8.12 (s, 3H), 7.07 – 
6.86 (m, 4H), 3.63 – 3.36 (m, 4H), 3.26 – 3.00 (m, 6H), 3.00 – 2.77 (m, 1H), 1.95 (d, J = 10.3 
Hz, 2H), 1.77 (d, J = 11.9 Hz, 2H), 1.71 – 1.55 (m, 2H), 1.44 – 1.14 (m, 3H), 1.14 – 0.82 (m, 
2H); 13C NMR (d6-DMSO) δ 151.8 (C), 139.4 (C), 123.5 (CH), 120.8 (CH), 118.2 (CH), 
112.0 (CH), 55.4 (CH3), 53.7 (CH2), 51.0 (CH2), 49.2 (CH), 46.8 (CH2), 33.8 (CH), 30.0 
(CH2), 29.9 (CH2), 29.5 (CH2). 
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(trans)-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexan-1-amine 
trihydrochloride (11j). Following the same conditions as in the synthesis of (trans)-4-(2-(4-
(2-methoxyphenyl)piperazin-1-yl)ethyl)cyclohexan-1-amine trihydrochloride (11i), using 
tert-butyl ((trans)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)carbamate 
(10j) as starting material, gave 227 mg of white solid (95%). 1H NMR (d6-DMSO) δ 11.30 (s, 
1H), 8.11 (d, J = 3.9 Hz, 3H), 7.44 – 7.29 (m, 2H), 7.19 (dd, J = 7.1/ 2.5 Hz, 1H), 3.55 (d, J = 
11.4 Hz, 2H), 3.44 – 3.31 (m, 3H), 3.25 (t, J = 11.7 Hz, 2H), 3.19 – 3.02 (m, 3H), 2.92 (d, J = 
4.7 Hz, 1H), 1.95 (d, J = 10.4 Hz, 2H), 1.77 (d, J = 11.7 Hz, 2H), 1.72 – 1.57 (m, 2H), 1.47 – 
1.17 (m, 3H), 1.14 – 0.86 (m, 2H); 13C NMR (d6-DMSO) δ 149.6 (C), 132.7 (C), 128.7 (CH), 
126.0 (C), 125.3 (CH), 119.8 (CH), 53.6 (CH2), 51.0 (CH2), 49.2 (CH), 47.6 (CH2), 33.8 
(CH), 30.0 (CH2), 29.9 (CH2), 29.5 (CH2). 
N-((trans)-4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-
carboxamide (12b). Following General Procedure E using (trans)-4-(2-(3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine (11b, 40 mg, 155 µmol) as the amine, 
and 1H-indole-2-carboxylic acid (30 mg, 186 µmol). Purification by flash column 
chromatography (EtOAc) gave the title compound as a white solid (19 mg, 31%). 1H NMR 
(d6-DMSO) δ 11.49 (br s, 1H), 8.17 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.41 (dd, J 
= 8.2/0.7 Hz, 1H), 7.19 – 6.98 (m, 7H), 3.82 – 3.69 (m, 1H), 3.53 (s, 2H), 2.80 (t, J = 5.7 Hz, 
2H), 2.64 (t, J = 5.9 Hz, 2H), 2.49 – 2.44 (m, 2H), 1.93 – 1.77 (m, 4H), 1.46 (dd, J = 14.5/6.8 
Hz 2H), 1.41 – 1.25 (m, 3H), 1.06 (m, 2H). 13C NMR (d6-DMSO) δ 160.2 (C), 136.3 (C), 
135.0 (C), 132.0 (C), 128.4 (C), 127.1 (CH), 126.4 (C), 125.9 (CH), 125.4 (CH), 123.1 (CH), 
121.4 (CH), 119.6 (CH), 112.28 (CH), 112.23 (CH), 102.4 (CH), 55.7 (CH2), 55.4 (CH2), 
50.6 (CH2), 48.2 (CH), 34.8 (CH), 33.7 (CH2), 32.3 (CH2), 31.7 (CH2), 28.7 (CH2). HRMS 
(m/z): [MH]+ calcd. for C26H31N3O, 402.2540; found 402.2560. 
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N-(trans-4-(2-(7-Fluoro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-
2-carboxamide (12c). Following General Procedure E using (trans)-4-(2-(7-fluoro-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine (11c) (88 mg, 318 µmol) as the amine, 
and 1H-indole-2-carboxylic acid. Purification by flash column chromatography (EtOAc) gave 
the title compound as a white solid (70 mg, 52%). 1H NMR (d6-DMSO) δ 11.50 (d, J = 1.4 
Hz, 1H), 8.18 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.42 (dd, J = 8.2/0.8 Hz, 1H), 
7.21 – 7.08 (m, 3H), 7.02 (ddd, J = 8.0/7.1/1.0 Hz, 1H), 6.98 – 6.86 (m, 2H), 3.77 (dtt, J = 
15.6/8.0/3.9 Hz, 1H), 3.53 (s, 2H), 2.77 (t, J = 5.5 Hz, 2H), 2.64 (t, J = 5.8 Hz, 2H), 2.50 – 
2.42 (m, 2H), 1.94 – 1.76 (m, 4H), 1.45 (dd, J = 14.6/6.8 Hz, 2H), 1.41 – 1.23 (m, 4H), 1.14 – 
1.00 (m, 2H). 13C NMR (d6-DMSO) δ 161.4 (C), 160.2 (C), 159.0 (C), 136.3 (C), 132.0 (C), 
130.3 (C, d, JCF = 2.6 Hz), 130.1 (CH. d, JCF = 8.0 Hz), 127.1 (C), 123.1 (CH), 121.4 (CH), 
119.6 (CH), 113.0 – 112.5 (2 × CH), 112.2 (CH), 102.4 (CH), 55.4 (2 × CH2), 50.5 (CH2), 
48.2 (CH), 34.8 (CH), 33.7 (CH2), 32.3 (CH2), 31.7 (CH2), 28.0 (CH2). HRMS (m/z): [MH]
+ 
calcd. for C26H30FN3O, 420.2446; found 420.2453. 
N-(trans-4-(2-(7-Chloro-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-
2-carboxamide (12d). Following General Procedure E using (trans)-4-(2-(7-chloro-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine (11d) as the amine, and 1H-indole-2-
carboxylic acid. Purification by flash column chromatography (EtOAc) gave the title 
compound as a white solid (42 mg, 43%). 1H NMR (d6-DMSO) δ 11.50 (d, J = 1.4 Hz, 1H), 
8.18 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.42 (dd, J = 8.2/0.8 Hz, 1H), 7.20 – 7.09 
(m, 5H), 7.02 (ddd, J = 8.0/7.0/0.9 Hz, 1H), 3.76 (dtt, J = 15.2/7.7/3.7 Hz, 1H), 3.53 (s, 2H), 
2.78 (t, J = 5.7 Hz, 2H), 2.64 (t, J = 5.8 Hz, 2H), 2.50 – 2.44 (m, 2H), 1.95 – 1.74 (m, 4H), 
1.45 (dd, J = 14.5/6.8 Hz, 2H), 1.42 – 1.21 (m, 3H), 1.11 – 1.02 (m, 2H). 13C NMR (d6-
DMSO) δ 160.2 (C), 137.4 (C), 136.3 (C), 133.3 (C), 132.0 (C), 130.2 (CH), 129.8 (C), 127.1 
(C), 126.1 (CH), 125.8 (CH), 123.1 (CH), 121.4 (CH), 119.6 (CH), 112.2 (CH), 102.4 (CH), 
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55.4 (CH2), 55.1 (CH2), 50.2 (CH2), 48.2 (CH), 34.7 (CH), 33.6 (CH2), 32.3 (CH2), 31.7 
(CH2), 28.1 (CH2). HRMS (m/z): [MH]
+ calcd. for C26H30ClN3O, 436.2150; found 436.2144. 
N-(trans-4-(2-(7-Bromo-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-
2-carboxamide (12e). Following General Procedure E using (trans)-4-(2-(7-bromo-3,4-
dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine (11e) as the amine, and 1H-indole-2-
carboxylic acid. Purification by flash column chromatography (gradient EtOAc:Pet. spirits, 
1:1, v/v, to 100% EtOAc) gave the title compound as a white solid (26 mg, 25%). 1H NMR 
(d6-DMSO) δ 11.50 (d, J = 1.1 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 
7.42 (dd, J = 8.2/0.6 Hz, 1H), 7.33 – 7.22 (m, 2H), 7.21 – 7.13 (m, 2H), 7.09 – 6.99 (m, 2H), 
3.76 (dtt, J = 15.3/7.7/3.7 Hz, 1H), 3.54 (s, 2H), 2.76 (t, J = 5.5 Hz, 2H), 2.64 (t, J = 5.6 Hz, 
2H), 2.50 – 2.42 (m, 2H), 1.92 – 1.74 (m, 4H), 1.45 (dd, J = 14.4/6.9 Hz, 2H), 1.41 – 1.24 (m, 
3H), 1.06 (m, 2H). 13C NMR (d6-DMSO) δ 160.2 (C), 137.8 (C), 136.3 (C), 133.8 (C), 132.0 
(C), 130.6 (CH), 129.0 (CH), 128.7 (CH), 127.1 (C), 123.1 (CH), 121.4 (CH), 119.6 (CH), 
118.2 (C), 112.2 (CH), 102.4 (CH), 55.3 (CH2), 55.0 (CH2), 50.2 (CH2), 48.2 (CH), 34.7 
(CH), 33.6 (CH2), 32.3 (CH2), 31.7 (CH2), 28.1 (CH2). HRMS (m/z): [MH]
+ calcd. for 
C26H30BrN3O, 480.1645; found 480.1647. 
N-(trans-4-(2-(7-(Trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-
1H-indole-2-carboxamide (12f). Following General Procedure E using (trans)-4-(2-(7-
(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexanamine (11f) as the amine, 
and 1H-indole-2-carboxylic acid. Purification by flash column chromatography (EtOAc) gave 
the title compound as a white solid (84 mg, 79%). 1H NMR (d6-DMSO) δ 11.51 (s, 1H), 8.18 
(d, J = 8.1 Hz, 1H), 7.59 (d, J = 8.3 Hz, 1H), 7.48 – 7.39 (m, 3H), 7.32 (d, J = 8.5 Hz, 1H), 
7.20 – 7.11 (m, 2H), 7.05 – 6.98 (m, 1H), 3.85 – 3.70 (m, 1H), 3.62 (s, 2H), 2.88 (t, J = 5.3 
Hz, 2H), 2.67 (t, J = 5.8 Hz, 2H), 2.51 – 2.45 (m, 2H), 1.94 – 1.76 (m, 4H), 1.46 (dd, J = 
14.4/6.8 Hz, 2H), 1.42 – 1.22 (m, 3H), 1.06 (m, 2H). 13C NMR (d6-DMSO) δ 160.7 (C), 
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139.8 (C), 136.8 (C), 136.7 (C), 132.5 (C), 129.8 (CH), 127.5 (C), 126.7 (C, q, JCF = 31.5 
Hz), 124.9 (C, q, JCF = 272 Hz), 123.7 (CH, q, JCF = 3.6 Hz), 123.6 (CH), 122.9 (CH, q, JCF = 
3.6 Hz), 121.8 (CH), 120.1 (CH), 112.7 (CH), 102.9 (CH), 55.8 (CH2), 55.6 (CH2), 50.5 
(CH2), 48.7 (CH), 35.2 (CH), 34.1 (CH), 32.8 (CH2), 32.2 (CH2), 29.1 (CH2). HRMS (m/z): 
[MH]+ calcd. for C27H30F3N3O, 470.2414; found 470.2420. 
N-(trans-4-(2-(4,5-Dihydro-1H-benzo[c]azepin-2(3H)-yl)ethyl)cyclohexyl)-1H-indole-2-
carboxamide (12g). Following General Procedure E using (trans)-4-(2-(4,5-dihydro-1H-
benzo[c]azepin-2(3H)-yl)ethyl)cyclohexanamine (11g) as the amine, and 1H-indole-2-
carboxylic acid. Purification by flash column chromatography (EtOAc, gradient to 
EtOAc:MeOH, 4:1, v/v), gave the product as a yellow solid which required further 
purification. The solid was taken in DMSO (0.5 mL), and water (3 mL) added to the solution. 
The product was collected by filtration, and washed with water (10 mL) to give the title 
compound as a white solid (15 mg, 22%). 1H NMR (d6-DMSO) δ 11.53 (d, J = 1.4 Hz, 1H), 
8.19 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.42 (dd, J = 8.2/0.8 Hz, 1H), 7.20 – 7.06 
(m, 6H), 7.02 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 3.82 (s, 2H), 3.74 (dtt, J = 15.5/7.9/3.8 Hz, 1H), 
3.08 – 2.98 (m, 2H), 2.88 – 2.80 (m, 2H), 2.37 – 2.20 (m, 2H), 1.89 – 1.79 (m, 2H), 1.73 (d, J 
= 11.5 Hz, 2H), 1.65 – 1.57 (m, 2H), 1.40 – 1.14 (m, 5H), 1.08 – 0.92 (m, 2H). 13C NMR (d6-
DMSO) δ 160.2 (C), 142.7 (C), 139.3 (C), 136.3 (C), 132.0 (C), 129.5 (CH), 128.6 (CH), 
127.1 (C), 126.9 (CH), 125.6 (CH), 123.1 (CH), 121.4 (CH), 119.6 (CH), 112.2 (CH), 102.5 
(CH), 58.5 (CH2), 58.4 (CH2), 50.1 (CH2), 48.2 (CH), 35.4 (CH2), 34.5(CH), 33.9 (CH2), 32.3 
(CH2), 31.7 (CH2), 24.6 (CH2). HRMS (m/z): [MH]
+ calcd. for C27H33N3O, 416.2696; found 
416.2704. 
N-(trans-4-(2-(6,7-Dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethyl)cyclohexyl)-1H-indole-
2-carboxamide (12h). Following General Procedure E using (trans)-4-(2-(6,7-
dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethyl)cyclohexanamine (11h) as the amine, and 1H-
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indole-2-carboxylic acid. Purification by flash column chromatography (EtOAc) gave the 
title compound as a white solid (17 mg, 28%). 1H NMR (d6-DMSO) δ 11.50 (d, J = 1.4 Hz, 
1H), 8.18 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.42 (dd, J = 8.2/0.7 Hz, 1H), 7.26 (d, 
J = 5.1 Hz, 1H), 7.20 – 7.12 (m, 2H), 7.02 (ddd, J = 8.0/7.0/0.9 Hz, 1H), 6.79 (d, J = 5.1 Hz, 
1H), 3.76 (dtt, J = 15.4/7.8/3.8 Hz, 1H), 3.45 (s, 2H), 2.79 (t, J = 5.1 Hz, 2H), 2.70 (t, J = 5.6 
Hz, 2H), 2.54 – 2.51 (m, 2H), 1.95 – 1.70 (m, 4H), 1.45 (dd, J = 14.5/6.8 Hz, 2H), 1.41 – 
1.23 (m, 3H), 1.12 – 1.00 (m, 2H). 13C NMR (d6-DMSO) δ 160.2 (C), 136.3 (C), 134.2 (C), 
132.8 (C), 132.0 (C), 127.1 (C), 125.5 (CH), 123.1 (CH), 122.9 (CH), 121.4 (CH), 119.6 
(CH), 112.2 (CH), 102.4 (CH), 55.0 (CH2), 52.6 (CH2), 50.6 (CH2), 48.2 (CH), 34.7 (CH), 
33.9 (CH2), 32.3 (CH2), 31.7 (CH2), 25.1 (CH2). HRMS (m/z): [MH]
+ calcd. for C24H29N3OS, 
408.2104; found 408.2106. 
N-((trans)-4-(2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl)cyclohexyl)-1H-indole-2-
carboxamide (12i). Following General Procedure E using (trans)-4-(2-(4-(2-
methoxyphenyl)piperazin-1-yl)ethyl)cyclohexan-1-amine (11i) as the amine and 1H-indole-
2-carboxylic acid. Flash column chromatography purification (eluent MeOH/DCM 0:100 to 
5:95) gave the title compound as a pale brown solid (76mg, 63%). 1H NMR (d6-DMSO ) δ 
11.50 (d, J = 1.5 Hz, 1H), 8.18 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.41 (dd, J = 
8.2/0.8 Hz, 1H), 7.22 – 7.09 (m, 2H), 7.02 (ddd, J = 8.0/7.1/1.0 Hz, 1H), 6.98 – 6.81 (m, 4H), 
3.91 – 3.60 (m, 4H), 2.95 (s, 4H), 2.73 – 2.19 (m, 6H), 2.07 – 1.68 (m, 4H), 1.55 – 1.19 (m, 
5H), 1.17 – 0.92 (m, 2H). 13C NMR (d6-DMSO) δ 160.2  (C), 152.0 (C), 142.0 (C), 136.3 
(C), 132.0 (C), 127.1 (C), 123.1 (CH), 122.3 (CH), 121.4 (CH), 120.8 (CH), 119.6 (CH), 
117.9 (CH), 112.2 (CH), 111.9 (CH), 102.4 (CH), 55.8 (CH2), 55.3 (CH3), 53.1 (CH2), 50.1 
(CH2), 48.2 (CH), 34.8 (CH), 33.5 (CH2), 32.3 (CH2), 31.7 (CH2). m/z MS (TOF ES
+) 
C28H37N4O2 [MH]
+ calculated 461.3; found 461.3. LCMS tR: 3.20 min (system B). 
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N-((trans)-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1H-indole-2-
carboxamide (12j). Following General Procedure E using (trans)-4-(2-(4-(2,3-
dichlorophenyl)piperazin-1-yl)ethyl)cyclohexan-1-amine (11j) as the amine and 1H-indole-2-
carboxylic acid. Flash column chromatography purification (eluent MeOH/DCM 0:100 to 
5:95) gave the title compound as a pale brown solid (93mg, 81%). 1H NMR (d6-DMSO) δ 
11.50 (d, J = 1.5 Hz, 1H), 8.18 (d, J = 8.1 Hz, 1H), 7.59 (d, J = 8.2 Hz, 1H), 7.41 (dd, J = 
8.2/0.8 Hz, 1H), 7.36 – 7.25 (m, 2H), 7.21 – 7.08 (m, 3H), 7.02 (ddd, J = 8.0/7.1/0.9 Hz, 1H), 
3.75 (ddd, J = 11.7/9.8/6.0 Hz, 1H), 2.98 (s, 4H), 2.72 – 2.43 (m, 4H), 2.38 (t, J = 7.3 Hz, 
2H), 2.04 – 1.66 (m, 4H), 1.53 – 1.16 (m, 5H), 1.16 – 0.92 (m, 2H); 13C NMR (d6-DMSO) δ 
160.1 (C), 151.2 (C), 138.3 (C), 136.3 (C), 132.6 (C), 132.0 (C), 128.4 (CH), 127.1 (C), 
124.3 (CH), 123.1 (CH), 121.4 (CH), 119.6 (CH), 119.6 (CH), 112.2 (CH), 102.4 (CH), 55.7 
(CH2), 52.9 (CH2), 51.0 (CH2), 48.2 (CH), 34.7 (CH), 33.5 (CH2), 32.3 (CH2), 31.7 (CH2). 
m/z MS (TOF ES+) C27H33N4O [MH]
+ calculated 499.2; found 499.2. LCMS tR: 3.44 min 
(system B). 
tert-Butyl (3-bromopropyl)carbamate (14a). Following General Procedure C using 3-
bromopropylamine hydrobromide (13a) afforded the title compound as a yellow oil (1.98 g, 
91% yield). 1H NMR δ 4.78 (s, 1H), 3.44 (t, J = 6.5 Hz, 2H), 3.27 (q, J = 6.3 Hz, 2H), 2.05 
(p, J = 6.5 Hz, 2H) 1.44 (s, 9H). 13C NMR δ 155.9 (C), 85.2 (C), 39.1 (CH2), 32.8 (CH2), 
30.9 (CH2), 28.5 (CH3). 
tert-Butyl (4-hydroxybutyl)carbamate (14b). Following General Procedure C using 4-
aminobutanol (13b) afforded the title compound as a clear oil (283 mg, 93%). 1H NMR δ 
4.65 (s, 1H), 3.67 (t, J = 6.0 Hz, 2H), 3.16 (dd, J = 12.1/6.2 Hz, 2H), 1.78 (s, 1H), 1.68 – 1.51 
(m, 4H), 1.51 – 1.38 (m, 9H). 13C NMR δ 156.3 (C), 79.3 (C), 62.6 (CH2), 40.4 (CH2), 29.9 
(CH2), 28.6 (CH3), 26.8 (CH2). 
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tert-Butyl (5-hydroxypentyl)carbamate (14c). Following General Procedure C using 5-
aminopentanol (13c) afforded the title compound as a clear oil (440 mg, 47%). 1H NMR δ 
4.71 (s, 1H), 3.63 (t, J = 6.4 Hz, 2H), 3.12 (dd, J = 12.8/6.4 Hz, 2H), 2.30 (s, 1H), 1.62 – 1.54 
(m, 2H), 1.54 – 1.46 (m, 2H), 1.45 (d, J = 6.9 Hz, 9H), 1.42 – 1.35 (m, 2H). 13C NMR δ 
156.2 (C), 79.2 (C), 62.5 (CH2), 40.5 (CH2), 32.3 (CH2), 29.9 (CH2), 28.5 (CH3), 23.0 (CH2). 
tert-Butyl (6-hydroxyhexyl)carbamate (14d). Following General Procedure C using 6-
aminohexanol (13d) afforded the title compound as a clear oil (446 mg, 90%). 1H NMR δ 
4.53 (s, 1H), 3.64 (t, J = 6.1 Hz, 2H), 3.12 (dd, J = 12.9/6.6 Hz, 2H), 1.61 – 1.53 (m, 2H), 
1.53 – 1.45 (m, 3H), 1.44 (s, 9H), 1.41 – 1.31 (m, 4H). 13C NMR δ 156.1 (C), 79.1 (C), 62.7 
(CH2), 40.4 (CH2), 32.6 (CH2), 30.1 (CH2), 28.4 (CH3), 26.4 (CH2), 25.3 (CH2). 
4-((tert-Butoxycarbonyl)amino)butyl methanesulfonate (15b). Following General 
Procedure D using tert-butyl (4-hydroxybutyl)carbamate (14b) gave the title compound as a 
colourless oil (196 mg, 93%). 1H NMR δ 4.66 (br s, 1H), 4.25 (t, J = 6.4 Hz, 2H), 3.22 – 3.11 
(m, 2H), 3.02 (s, 3H), 1.84 – 1.74 (m, 2H), 1.68 – 1.52 (m, 2H), 1.43 (s, 9H). 13C NMR δ 
156.1 (C), 69.7 (CH2), 39.8 (CH2), 37.4 (CH3), 28.5 (CH3), 26.5 (CH2), 26.3 (CH2). 
5-((tert-Butoxycarbonyl)amino)pentyl methanesulfonate (15c). Following General 
Procedure D using tert-butyl (5-hydroxypentyl)carbamate (14c) afforded the title compound 
as a yellow oil (521 mg, 86%). 1H NMR δ 4.57 (s, 1H), 4.23 (t, J = 6.4 Hz, 2H), 3.13 (dd, J = 
12.8/6.5 Hz, 2H), 3.01 (s, 3H), 1.83 – 1.73 (m, 2H), 1.56 – 1.48 (m, 2H), 1.48 – 1.36 (m, 
11H). 13C NMR δ 156.0 (C), 79.2 (C), 69.8 (CH2), 40.2 (CH2), 37.4 (CH3), 29.5 (CH2), 28.8 
(CH2), 28.4 (CH3), 22.7 (CH2). 
6-((tert-Butoxycarbonyl)amino)hexyl methanesulfonate (15d). Following General 
Procedure D using tert-butyl (6-hydroxyhexyl)carbamate (14d) gave the title as a yellow oil 
(363 mg, 89%). 1H NMR δ 4.56 (br s, 1H), 4.22 (t, J = 6.5 Hz, 2H), 3.11 (dd, J = 12.9/6.5 Hz, 
2H), 3.01 (s, 3H), 1.82 – 1.70 (m, 2H), 1.55 – 1.29 (m, 15H). 13C NMR δ 156.1 (C), 79.2 (C), 
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70.0 (CH2), 40.5 (CH2), 37.5 (CH3), 30.0 (CH2), 29.2 (CH2), 28.5 (CH3), 26.3 (CH2), 25.2 
(CH2). 
tert-Butyl (3-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)propyl)carbamate (16a). To a 
solution of 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (9a) (100 mg, 632 µmol) in MeCN 
(20 mL) was added tert-butyl (3-bromopropyl)carbamate (14a) (151 mg, 632 µmol), 
followed by K2CO3 (175 mg, 1.26 mmol), and the mixture was heated at reflux. After 16 h, 
the solvent was removed in vacuo, then the product taken in EtOAc (20 mL) and washed with 
1 M K2CO3 (2 × 15 mL), brine (15 mL) then dried and concentrated in vacuo to give a yellow 
oil. The product was then purified by CombiFlash® Rf 200 (gradient 0-100% EtOAc in Pet. 
Spirits, 18 min) to give the product as a colourless oil (82 mg, 41%). 1H NMR δ 7.40 (dd, J = 
7.9/1.6 Hz, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 5.15 (s, 1H), 3.62 (s, 2H), 3.23 (dd, J 
= 12.2/6.0 Hz, 2H), 2.95 (t, J = 5.8 Hz, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.59 (t, J = 6.8 Hz, 2H), 
1.76 (p, J = 6.7 Hz, 2H), 1.42 (s, 9H). 13C NMR δ 156.1 (C), 140.4 (C), 136.3 (C), 130.5 
(CH), 129.7 (CH), 129.6 (CH), 119.2 (C), 109.5 (C), 79.1 (C), 56.2 (CH2), 55.8 (CH2), 50.1 
(CH2), 39.6 (CH2), 29.5 (CH2), 28.5 (CH3), 27.1 (CH2). HRMS (m/z): [MH]
+ calcd. for 
C18H25N3O2, 316.2020; found 316.2029. 
tert-Butyl (4-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)butyl)carbamate (16b). To a 
solution of 4-((tert-butoxycarbonyl)amino)butyl methanesulfonate (15b) (202 mg, 756 µmol) 
in DCM (15 mL) was added 1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (9a) (131 mg, 828 
µmol), followed by DIPEA (156 µL, 907 µmol). The solution was heated at reflux for 3 d, 
then concentrated in vacuo and the product purified by flash column chromatography 
(EtOAc) to give the title compound as a yellow oil (36 mg, 14%). 1H NMR δ 7.40 (dd, J = 
7.9/1.6 Hz, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 4.99 (s, 1H), 3.62 (s, 2H), 3.15 (dd, J 
= 12.2/6.1 Hz, 2H), 2.96 (t, J = 5.8 Hz, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.54 (t, J = 7.0 Hz, 2H), 
1.71 – 1.50 (m, 4H), 1.42 (s, 9H). 13C NMR δ 156.2 (C), 140.4 (C), 136.3 (C), 130.5 (CH), 
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129.73 (CH), 129.65 (CH), 119.2 (C), 109.5 (CH), 79.1 (C), 57.8 (CH2), 55.5 (CH2), 50.3 
(CH2), 40.5 (CH2), 29.5 (CH2), 28.5 (CH3), 28.0 (CH2), 24.5 (CH2). 
tert-Butyl (5-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)pentyl)carbamate (16c). 
Following the same conditions as in the synthesis of tert-butyl (4-(7-cyano-3,4-
dihydroisoquinolin-2(1H)-yl)butyl)carbamate (16b), using 5-((tert-
butoxycarbonyl)amino)pentyl methanesulfonate (15c) as starting material, afforded the title 
compound as a yellow oil (168 mg, 52%). 1H NMR δ 7.40 (dd, J = 7.9/1.6 Hz, 1H), 7.33 (s, 
1H), 7.20 (d, J = 7.9 Hz, 1H), 4.65 (s, 1H), 3.66 (s, 2H), 3.12 (dd, J = 12.9/6.4 Hz, 2H), 2.97 
(t, J = 5.8 Hz, 2H), 2.78 (t, J = 5.9 Hz, 2H), 2.59 – 2.49 (m, 2H), 1.62 (dt, J = 15.1/7.5 Hz, 
2H), 1.52 (dt, J = 14.7/7.3 Hz, 2H), 1.47 – 1.33 (m, 11H). 13C NMR δ 156.1 (C), 140.1 (C), 
135.9 (C), 130.5 (CH), 129.7 (CH), 129.6 (CH), 119.1 (C), 109.5 (C), 79.1 (C), 57.9 (CH2), 
55.3 (CH2), 50.1 (CH2), 40.5 (CH2), 30.0 (CH2), 29.2 (CH2), 28.5 (CH3), 26.5 (CH2), 24.6 
(CH2). HRMS (m/z): [MH]
+ calcd. for C20H29N3O2, 344.2333; found 344.2346.  
tert-Butyl (6-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)hexyl)carbamate (16d). 
Following the same conditions as in the synthesis of tert-butyl (4-(7-cyano-3,4-
dihydroisoquinolin-2(1H)-yl)butyl)carbamate (16b), using 6-((tert-
butoxycarbonyl)amino)hexyl methanesulfonate (15d) as starting material. The product was 
purified using CombiFlash® Rf 200 (gradient 0-70% EtOAc in Pet. Spirits, 20 min) to give 
the title compound as a pale yellow oil (81 mg, 24%). 1H NMR δ 7.40 (dd, J = 7.9/1.6 Hz, 
1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 4.52 (s, 1H), 3.61 (s, 2H), 3.12 (dd, J = 13.0/6.5 
Hz, 2H), 2.95 (t, J = 5.8 Hz, 2H), 2.73 (t, J = 5.9 Hz, 2H), 2.53 – 2.47 (m, 2H), 1.63 – 1.54 
(m, 2H), 1.52 – 1.42 (m, 11H), 1.40 – 1.32 (m, 4H). 13C NMR δ 156.1 (C), 140.5 (C), 136.5 
(C), 130.6 (CH), 129.69 (CH), 129.65 (CH), 119.3 (C), 109.5 (C), 79.2 (C), 58.3 (CH2), 55.7 
(CH2), 50.4 (CH2), 40.6 (CH2), 30.2 (CH2), 29.6 (CH2), 28.6 (CH3), 27.3 (CH2), 27.2 (CH2), 
26.8 (CH2). HRMS (m/z): [MH]
+ calcd. for C21H31N3O2, 358.2489; found 358.2498. 
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2-(3-Aminopropyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (17a). Following 
General Procedure B using tert-butyl (3-(7-cyano-3,4-dihydroisoquinolin-2(1H)-
yl)propyl)carbamate (16a) gave the title compound as a yellow oil (30 mg, 46%). 1H NMR δ 
7.40 (dd, J = 7.9/1.6 Hz, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 3.63 (s, 2H), 2.95 (t, J = 
5.8 Hz, 2H), 2.80 (t, J = 6.8 Hz, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.65 – 2.54 (m, 2H), 1.80 – 
1.68 (m, 2H), 1.42 (br s, 2H). 13C NMR δ 140.4 (C), 136.4 (C), 130.5 (CH), 129.64 (CH), 
129.59 (CH), 119.2 (C), 109.4 (C), 56.1 (CH2), 55.7 (CH2), 50.3 (CH2), 40.7 (CH2), 30.7 
(CH2), 29.5 (CH2). 
2-(5-Aminopentyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (17c). Following 
General Procedure B using tert-butyl (5-(7-cyano-3,4-dihydroisoquinolin-2(1H)-
yl)pentyl)carbamate (16c) gave the title compound as a yellow oil (103 mg, 99%). 1H NMR δ 
7.39 (dd, J = 7.9/1.6 Hz, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 3.61 (s, 2H), 2.95 (t, J = 
5.9 Hz, 2H), 2.80 – 2.64 (m, 4H), 2.52 (dd, J = 8.4/6.8 Hz, 2H), 1.61 (dt, J = 15.1/7.4 Hz, 
2H), 1.54 – 1.44 (m, 2H), 1.44 – 1.34 (m, 2H), 1.24 – 1.13 (m, 2H). 13C NMR δ 140.5 (C), 
136.5 (C), 130.5 (CH), 129.7 (CH), 129.6 (CH), 119.3 (C), 109.5 (C), 58.3 (CH2), 55.7 
(CH2), 50.4 (CH2), 42.3 (CH2), 33.9 (CH2), 29.6 (CH2), 27.1 (CH2), 24.9 (CH2). 
2-(6-Aminohexyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (17d). Following 
General Procedure B using tert-butyl (6-(7-cyano-3,4-dihydroisoquinolin-2(1H)-
yl)hexyl)carbamate (16d) gave the title compound as a yellow oil (42 mg, 99%). 1H NMR δ 
7.39 (dd, J = 7.9/1.6 Hz, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 3.61 (s, 2H), 2.95 (t, J = 
5.8 Hz, 2H), 2.71 (dt, J = 13.8/6.4 Hz, 4H), 2.56 – 2.47 (m, 2H), 1.65 – 1.54 (m, 2H), 1.52 – 
1.30 (m, 9H). 13C NMR δ 140.5 (C), 136.5 (C), 130.5 (CH), 129.63 (CH), 129.61 (CH), 119.2 
(C), 109.4 (CH), 58.3 (CH2), 55.7 (CH2), 50.3 (CH2), 42.3 (CH2), 33.8 (CH2), 29.6 (CH2), 
27.5 (CH2), 27.2 (CH2), 26.9 (CH2). 
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N-(3-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-1H-indole-2-carboxamide 
(18a). Following General Procedure E using 2-(3-aminopropyl)-1,2,3,4-
tetrahydroisoquinoline-7-carbonitrile (17a) as the amine, and 1H-indole-2-carboxylic acid. 
The product was purified using CombiFlash® Rf 200 (gradient 0-100% EtOAc in Pet. 
Spirits, 21 min) to give the title compound as a white solid (38 mg, 76%). 1H NMR (d6-
DMSO) δ 11.55 (s, 1H), 8.55 (t, J = 5.6 Hz, 1H), 7.61 – 7.51 (m, 3H), 7.42 (dd, J = 8.2/0.8 
Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.17 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 7.06 – 6.96 (m, 2H), 
3.61 (s, 2H), 3.42 – 3.35 (m, 2H), 2.90 (t, J = 5.7 Hz, 2H), 2.70 (t, J = 5.8 Hz, 2H), 2.56 (t, J 
= 7.0 Hz, 2H), 1.81 (p, J = 6.9 Hz, 2H). 13C NMR (d6-DMSO) δ 161.0 (C), 140.6 (C), 136.6 
(C), 136.3 (C), 131.9 (C), 130.4 (CH), 129.7 (CH), 129.5 (CH), 127.1 (C), 123.1 (CH), 121.4 
(CH), 119.7 (CH), 119.1 (C), 112.3 (CH), 108.2 (C), 102.1 (CH), 55.2 (CH2), 54.8 (CH2), 
49.8 (CH2), 37.4 (CH2), 29.0 (CH2), 26.5 (CH2). HRMS (m/z): [MH]
+ calcd. for C22H22N4O, 
359.1866; found 359.1874. 
N-(4-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-1H-indole-2-carboxamide 
(18b). Following General Procedure B using tert-butyl (4-(7-cyano-3,4-dihydroisoquinolin-
2(1H)-yl)butyl)carbamate (16b) (36 mg, 109 µmol) gave the deprotected product 17b which 
was immediately reacted according to General Procedure E. Purification by flash column 
chromatography (CHCl3:MeOH, 95:5, v/v) gave the product as a white solid (28 mg, 69%). 
1H NMR (d6-DMSO) δ 8.44 (t, J = 5.7 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.57 – 7.53 (m, 2H), 
7.41 (dq, J = 8.3/0.9 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 7.16 (ddd, J = 8.2/7.0/1.1 Hz, 1H), 
7.08 (dd, J = 2.1/0.7 Hz, 1H), 7.02 (ddd, J = 8.0/7.0/1.0 Hz, 1H), 3.57 (s, 2H), 3.32 – 3.28 (m, 
2H), 2.87 (t, J = 6.2 Hz, 2H), 2.66 (t, J = 5.8 Hz, 2H), 2.49 – 2.46 (m, 2H), 1.59 (dt, J = 
6.7/3.5 Hz, 4H). 13C NMR (d6-DMSO) δ 161.0 (C), 140.7 (C), 136.7 (C), 136.3 (C), 131.9 
(C), 130.3 (CH), 129.7 (CH), 129.4 (CH), 127.1 (C), 123.1 (CH), 121.4 (CH), 119.6 (CH), 
119.1 (C), 112.3 (CH), 108.2 (C), 102.2 (CH), 57.0 (CH2), 54.8 (CH2), 49.7 (CH2), 38.7 
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(CH2), 28.9 (CH2), 27.1 (CH2), 23.9 (CH2). HRMS (m/z): [MH]
+ calcd. for C23H24N4O, 
373.2023; found 373.2022. 
N-(5-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)pentyl)-1H-indole-2-carboxamide 
(18c). Following General Procedure E using 2-(5-aminopentyl)-1,2,3,4-
tetrahydroisoquinoline-7-carbonitrile (17c) as the amine, and 1H-indole-2-carboxylic acid. 
Purification by flash column chromatography (EtOAc, gradient to EtOAc:MeOH, 20:1, v/v) 
gave the title compound as a pale yellow oil (129 mg, 79%). 1H NMR δ 10.24 (s, 1H), 7.61 
(d, J = 8.0 Hz, 1H), 7.46 (dd, J = 8.3/0.8 Hz, 1H), 7.36 (dd, J = 7.9/1.6 Hz, 1H), 7.27 – 7.23 
(m, 2H), 7.16 – 7.09 (m, 2H), 6.86 (d, J = 1.3 Hz, 1H), 6.60 (t, J = 5.8 Hz, 1H), 3.53 (dd, J = 
12.8/6.4 Hz, 4H), 2.92 – 2.88 (m, 2H), 2.68 (t, J = 5.9 Hz, 2H), 2.55 – 2.46 (m, 2H), 1.75 – 
1.57 (m, 4H), 1.51 – 1.40 (m, 2H). 13C NMR δ 162.0 (C), 140.4 (C), 136.6 (C), 136.3 (C), 
131.0 (C), 130.5 (CH), 129.60 (CH), 129.56 (CH), 127.7 (C), 124.3 (CH), 121.9 (CH), 120.6 
(CH), 119.3 (C), 112.2 (CH), 109.3 (C), 102.1 (CH), 58.0 (CH2), 55.5 (CH2), 50.2 (CH2), 
39.7 (CH2), 29.7 (CH2), 29.4 (CH2), 26.7 (CH2), 24.8 (CH2). HRMS (m/z): [MH]
+ calcd. for 
C24H26N4O, 387.2179; found 387.2194. 
N-(6-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)hexyl)-1H-indole-2-carboxamide 
(18d). Following General Procedure E using 2-(6-aminohexyl)-1,2,3,4-
tetrahydroisoquinoline-7-carbonitrile (17d) as the amine, and 1H-indole-2-carboxylic acid. 
Purification by flash column chromatography (EtOAc) gave the title compound as a white 
wax (36 mg, 45%). 1H NMR δ 9.92 (s, 1H), 7.63 (dd, J = 8.0/0.7 Hz, 1H), 7.46 (dd, J = 
8.3/0.8 Hz, 1H), 7.37 (dd, J = 7.9/1.6 Hz, 1H), 7.30 – 7.26 (m, 2H), 7.18 – 7.09 (m, 2H), 6.90 
– 6.81 (m, 1H), 6.33 (t, J = 5.7 Hz, 1H), 3.56 (s, 2H), 3.52 (dd, J = 13.3/7.0 Hz, 2H), 2.91 (t, 
J = 5.8 Hz, 2H), 2.70 (t, J = 5.9 Hz, 2H), 2.55 – 2.39 (m, 2H), 1.72 – 1.53 (m, 4H), 1.50 – 
1.35 (m, 4H). 13C NMR δ 161.9 (C), 140.5 (C), 136.53 (C), 136.47 (C), 131.0 (C), 130.5 
(CH), 129.7 (CH), 129.6 (CH), 127.7 (C), 124.5 (CH), 121.9 (CH), 120.7 (CH), 119.3 (C), 
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112.2 (CH), 109.4 (C), 101.8 (CH), 58.2 (CH2), 55.6 (CH2), 50.3 (CH2), 39.8 (CH2), 29.8 
(CH2), 29.5 (CH2), 27.3 (CH2), 27.1 (CH2), 27.0 (CH2). HRMS (m/z): [MH]
+ calcd. for 
C25H28N4O, 401.2336; found 401.2346. 
Ethyl 2-(trans-4-((tert-butoxycarbonyl)(methyl)amino)cyclohexyl)acetate (19). To a 
solution of ethyl 2-((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)acetate (7)23 (200 mg, 
701 µmol) in dry DMF (5 mL) at 0 °C was added sodium hydride, 60% dispersion in mineral 
oil (280 mg, 7.01 mmol) that had been washed with Pet. spirits (3 × 15 mL). After 30 min, 
iodomethane (436 µL, 7.01 mmol) was slowly added and the mixture allowed to warm to RT. 
After 16 h, an additional portion of iodomethane (436 µL, 7.01 mmol) was added, and after 
40 h another portion (436 µL, 7.01 mmol). After an additional 24 h, the mixture was diluted 
with water (20 mL) and the product extracted into EtOAc (2 × 20 mL). The organic extracts 
were then washed with 1 M K2CO3 (2 × 20 mL), brine (2 × 20 mL), dried and concentrated in 
vacuo. The product was then purified by flash column chromatography (Pet. spirits:EtOAc, 
4:1, v/v) to give the product as a clear oil (75 mg, 36%). 1H NMR δ 4.12 (q, J = 7.1 Hz, 2H), 
3.89 (br s, 1H), 2.71 (s, 3H), 2.19 (d, J = 7.0 Hz, 2H), 1.88 – 1.77 (m, 2H), 1.77 – 1.63 (m, 
3H), 1.55 – 1.37 (m, 11H), 1.25 (t, J = 7.1 Hz, 3H), 1.12 (m, 2H). 13C NMR δ 172.9 (C), 
155.7 (C), 79.2 (C), 60.3 (CH2), 53.9 (CH), 41.6 (CH2), 34.2 (CH), 32.1 (CH2), 29.6 (CH2), 
28.6 (CH3), 28.3 (CH3), 14.4 (CH3). 
tert-Butyl methyl(trans-4-(2-oxoethyl)cyclohexyl)carbamate (20). To a solution of ethyl 
2-(trans-4-((tert-butoxycarbonyl)(methyl)amino)cyclohexyl)acetate (19) (75 mg, 250 µmol) 
in degassed toluene (10 mL) with bubbling N2 at -78 °C was slowly added DIBAL-H, 1 M in 
toluene (407 µL, 501 µmol). After 30 min, the mixture was quenched with CH3OH (5 mL) in 
toluene (10 mL), and warmed to RT with stirring for 15 min. Saturated potassium sodium 
tartrate solution (10 mL) was added and the mixture stirred vigorously for 30 min. The 
product was then extracted with Et2O (3 × 20 mL), and the combined organic extracts washed 
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with brine (20 mL), dried and concentrated in vacuo to give the title compound (64 mg, 
100%). 1H NMR δ 9.69 (t, J = 2.0 Hz, 1H), 3.97 – 3.77 (m, 1H), 2.65 (s, 3H), 2.26 (dd, J = 
6.3/2.0 Hz, 2H), 1.83 – 1.71 (m, 3H), 1.69 – 1.57 (m, 2H), 1.50 – 1.28 (m, 11H), 1.11 – 1.01 
(m, 2H). 13C NMR δ 202.2 (CH), 155.6 (C), 79.2 (C), 50.7 (CH2), 32.2 (CH2), 31.8 (CH), 
29.6 (CH2), 28.5 (CH3), 28.3 (CH3). 
tert-Butyl (trans-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl) 
(methyl)carbamate (21). Following General Procedure A, using 7-cyano-1,2,3,4-
tetrahydroisoquinoline (9a) as the amine, and tert-butyl methyl(trans-4-(2-
oxoethyl)cyclohexyl)carbamate (20) (1 eq.) as the aldehyde. Flash column chromatography 
(EtOAc) gave the title compound as a pale yellow oil (37 mg, 37%). 1H NMR δ 7.40 (dd, J = 
7.9/1.6 Hz, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 3.94 (s, 1H), 3.61 (s, 2H), 2.94 (t, J = 
5.8 Hz, 2H), 2.80 – 2.64 (m, 5H), 2.61 – 2.47 (m, 2H), 2.00 (s, 1H), 1.84 (d, J = 12.2 Hz, 
2H), 1.74 – 1.63 (m, 2H), 1.55 – 1.33 (m, 12H), 1.33 – 1.18 (m, 1H), 1.14 – 1.04 (m, 2H). 13C 
NMR δ 155.8 (C), 140.5 (C), 136.4 (C), 130.5 (CH), 129.7 (CH), 129.6 (CH), 119.2 (C), 
109.5 (C), 79.2 (C), 56.2 (CH2), 55.7 (CH2), 54.2 (CH), 50.4 (CH2), 35.4 (CH), 34.2 (CH2), 
32.5 (CH2), 29.8 (CH2), 29.5 (CH2), 28.6 (CH3), 28.3 (CH3). HRMS (m/z): [MH]
+ calcd. for 
C24H35N3O2, 398.2802; found 398.2814. 
N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-N-methyl-
1H-indole-2-carboxamide (23). tert-Butyl (trans-4-(2-(7-cyano-3,4-dihydroisoquinolin-
2(1H)-yl)ethyl)cyclohexyl)(methyl)carbamate (21) was treated to conditions in General 
Procedure B, then the crude product was immediately reacted following General Procedure E, 
using 1H-indole-2-carboxylic acid. Purification by flash column chromatography (EtOAc) 
gave the product as a white solid (12 mg, 34%). 1H NMR δ 9.40 (s, 1H), 7.66 (d, J = 7.5 Hz, 
1H), 7.44 (dd, J = 8.3/0.8 Hz, 1H), 7.41 (dd, J = 7.9/1.5 Hz, 1H), 7.33 (s, 1H), 7.31 – 7.26 
(m, 1H), 7.20 (d, J = 7.9 Hz, 1H), 7.14 (dd, J = 11.1/3.9 Hz, 1H), 6.81 (br s, 1H), 4.55 (br s, 
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1H), 3.63 (s, 2H), 3.31 – 3.02  (m, 2H), 2.96 (t, J = 5.7 Hz, 2H), 2.75 (t, J = 5.8 Hz, 2H), 2.61 
– 2.52 (m, 2H), 1.95 – 4.79 (m, 4H), 1.67 (br s, 2H), 1.55 (dd, J = 14.9/6.8 Hz, 2H), 1.40 – 
1.18 (m, 4H). HPLC, tR = 8.17 min, >99% purity. HRMS (m/z): [MH]
+ calcd. for C28H32N4O, 
441.2649; found 441.2659.  
N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)benzofuran-
2-carboxamide hydrochloride (25a). Following General Procedure E using 2-(2-((trans)-4-
aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (11a) (34 mg, 120 
µmol) as the amine, and benzofuran-2-carboxylic acid (24a). The product was purified by 
flash column chromatography (CHCl3:MeOH, 95:5, v/v) to give the product as a yellow oil 
(18 mg, 35%). For pharmacological testing, the product was converted to the hydrochloride 
salt by taking up the product in EtOAc (1 mL) and 1 M HCl in Et2O (1 mL). Removal of 
solvents revealed the hydrochloride salt as a white solid. 1H NMR (d6-DMSO) δ 11.12 (s, 
1H), 8.54 (d, J = 8.2 Hz, 1H), 7.79 – 7.71 (m, 3H), 7.65 (dd, J = 8.3/0.7 Hz, 1H), 7.55 (d, J = 
0.8 Hz, 1H), 7.52 – 7.40 (m, 2H), 7.37 – 7.30 (m, 1H), 4.58 (d, J = 16.0 Hz, 1H), 4.30 (dd, J 
= 15.6/7.9 Hz, 1H), 3.82 – 3.65 (m, 2H), 3.33 – 3.08 (m, 5H), 1.90 – 1.67 (m, 6H), 1.53 – 
1.27 (m, 3H), 1.16 – 1.00 (m, 2H). 13C NMR (d6-DMSO) δ 157.7 (C), 154.6 (C), 149.8 (C), 
138.2 (C), 131.4 (CH), 131.2 (CH), 130.8 (C), 130.3 (CH), 127.7 (C), 127.1 (CH), 124.1 
(CH), 123.1 (CH), 119.0 (C), 112.2 (CH), 109.8 (C), 109.7 (CH), 53.9 (CH2), 51.3 (CH2), 
48.52 (CH2), 48.48 (CH), 34.7 (CH), 32.2 (CH2), 31.7 (CH2), 30.5 (CH2), 25.6 (CH2). HRMS 
(m/z): [MH]+ calcd. for C27H29N3O2, 428.2334; found 428.2329. 
N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl) 
benzo[d]oxazole-2-carboxamide (25b). Following General Procedure E, using 2-(2-((trans)-
4-aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (11a) as the amine, 
and benzoxazole-2-carboxylic acid, potassium salt (24b). The product was  purified by flash 
column chromatography (CHCl3:MeOH, 98:2, v/v) to give the title compound as a clear oil 
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(26 mg, 16%). 1H NMR δ 7.81 – 7.76 (m, 1H), 7.68 – 7.62 (m, 1H), 7.48 (td, J = 7.8/1.5 Hz, 
1H), 7.45 – 7.40 (m, 2H), 7.34 (s, 1H), 7.21 (d, J = 7.9 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 
4.02 – 3.93 (m, 1H), 3.67 (s, 2H), 2.99 (t, J = 5.4 Hz, 2H), 2.84 – 2.74 (m, 2H), 2.67 – 2.51 
(m, 2H), 2.18 – 2.10 (m, 2H), 1.88 (d, J = 11.8 Hz, 2H), 1.57 (dd, J = 15.0/6.9 Hz, 2H), 1.45 
– 1.09 (m, 6H). 13C NMR δ 155.8 (C), 155.0 (C), 151.3 (C), 140.3 (C), 140.0 (C), 136.0 (C), 
130.6 (CH), 130.0 (CH), 129.7 (CH), 127.5 (CH), 125.7 (CH), 121.2 (CH), 119.1 (C), 112.0 
(CH), 109.8 (C), 56.0 (CH2), 55.3 (CH2), 50.2 (CH2), 49.3 (CH), 35.2 (CH), 33.7 (CH2), 32.8 
(CH2), 31.8 (CH2), 29.1 (CH2). HRMS (m/z): [MH]
+ calcd. for C26H28N4O2, 429.2285; found 
429.2275. 
N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indene-
2-carboxamide (25c). Following General Procedure E using 2-(2-((trans)-4-
aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (11a) as the amine, and 
indene-2-carboxylic acid (24c). Purification by flash column chromatography (EtOAc, 
gradient to 10:1 EtOAc:MeOH) gave the title compound as a brown solid (28 mg, 37%). 1H 
NMR δ 7.49 – 7.45 (m, 2H), 7.43 – 7.38 (m, 2H), 7.34 – 7.28 (m, 3H), 7.19 (d, J = 7.9 Hz, 
1H), 5.74 (d, J = 8.1 Hz, 1H), 3.95 – 3.81 (m, 1H), 3.66 (d, J = 1.4 Hz, 2H), 3.62 (s, 2H), 
2.99 – 2.92 (m, 2H), 2.74 (t, J = 5.9 Hz, 2H), 2.59 – 2.50 (m, 2H), 2.09 (d, J = 9.9 Hz, 2H), 
1.84 (d, J = 10.8 Hz, 2H), 1.57 – 1.48 (m, 2H), 1.38 – 1.08 (m, 5H). 13C NMR δ 164.2 (C), 
143.9 (C), 143.2 (C), 141.5 (C), 140.5 (C), 136.4 (C), 135.5 (CH), 130.5 (CH), 129.72 (CH), 
129.65 (CH), 127.98 (CH), 127.97 (CH), 124.3 (CH), 122.9 (CH), 119.3 (C), 109.5 (C), 56.2 
(CH2), 55.7 (CH2), 50.4 (CH2), 48.8 (CH), 38.3 (CH2), 35.4 (CH), 34.2 (CH2), 33.3 (CH2), 
32.0 (CH2), 29.5 (CH2). HRMS (m/z): [MH]
+ calcd. for C28H31N3O, 426.2540; found 
426.2543. 
N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1-methyl-
1H-indole-2-carboxamide (25d). Following General Procedure E using 2-(2-((trans)-4-
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aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (11a) (52 mg, 183 
µmol) as the amine, and 1-methylindole-2-carboxylic acid (24d). The product was purified 
by flash column chromatography (CHCl3:MeOH, 98:2, v/v) to give the product as a white 
solid (64 mg, 79%). 1H NMR δ 7.66 – 7.56 (m, 1H), 7.44 – 7.35 (m, 2H), 7.35 – 7.27 (m, 
2H), 7.19 (d, J = 8.1 Hz, 1H), 7.17 – 7.06 (m, 1H), 6.80 (s, 1H), 6.02 (d, J = 8.0 Hz, 1H), 
4.04 (s, 3H), 3.97 – 3.85 (m, 1H), 3.62 (s, 2H), 2.98 – 2.91 (m, 2H), 2.75 (t, J = 5.9 Hz, 2H), 
2.61 – 2.50 (m, 2H), 2.18 – 2.07 (m, 2H), 1.92 – 1.81 (m, 2H), 1.53 (dd, J = 15.1/7.0 Hz, 2H), 
1.41 – 1.31 (m, 1H), 1.31 – 1.08 (m, 4H). 13C NMR δ 162.0 (C), 140.4 (C), 139.1 (C), 132.5 
(C), 130.5 (CH), 129.8 (CH), 129.7 (CH), 126.1 (C), 124.1 (CH), 121.8 (CH), 120.6 (CH), 
119.3 (C), 110.2 (CH), 109.5 (C), 103.4 (CH), 98.5 (C), 56.2 (CH2), 55.7 (CH2), 50.4 (CH2), 
48.9 (CH), 35.4 (CH), 34.1 (CH2), 33.2 (CH2), 32.0 (CH2), 31.6 (CH3), 29.5 (CH2). HRMS 
(m/z): [MH]+ calcd. for C28H32N4O, 441.2644; found 441.2648. 
N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-
benzo[d]imidazole-2-carboxamide (25e). Following General Procedure E, using 2-(2-
((trans)-4-aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (11a) as the 
amine, and 1H-benzimidazole-2-carboxylic acid (24e). Purification by flash column 
chromatography (CHCl3:MeOH, 95:5, v/v) gave the product as a yellow solid (67 mg, 58%). 
For further purification, the solid was taken up in MeOH (1 mL) and the remaining 
precipitate collected by filtration and washed with MeOH (5 mL) to give a white solid. 1H 
NMR (d6-DMSO) δ 8.66 (d, J = 8.6 Hz, 1H), 7.70 (d, J = 7.8 Hz, 1H), 7.59 – 7.49 (m, 3H), 
7.34 – 7.20 (m, 3H), 3.85 – 3.71 (m, 1H), 3.57 (s, 2H), 2.88 (t, J = 5.4 Hz, 2H), 2.50 – 2.45 
(m, 2H), 2.66 (t, J = 5.9 Hz, 2H), 1.87 – 1.73 (m, 4H), 1.55 – 1.37 (m, 4H), 1.35 – 1.18 (m, 
1H), 1.15 – 0.96 (m, 2H). 13C NMR (d6-DMSO) δ 157.8 (C), 145.9 (C), 142.5 (C), 140.7 (C), 
136.7 (C), 134.4 (C), 130.4 (CH), 129.7 (CH), 129.4 (CH), 124.0 (CH), 122.5 (CH), 119.8 
(CH), 119.1 (C), 112.5 (CH), 108.2 (C), 55.3 (CH2), 54.8 (CH2), 49.8 (CH2), 48.3 (CH), 34.4 
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(CH), 33.6 (CH2), 31.8 (CH2), 31.7 (CH2), 28.9 (CH2). HRMS (m/z): [MH]
+ calcd. for 
C26H29N5O, 428.2445; found 428.2438.  
N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-
pyrrolo[2,3-b]pyridine-2-carboxamide dihydrochloride (25f). Following General 
Procedure E using 2-(2-((trans)-4-aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-
carbonitrile (11a) as the amine, and pyrrolo[2,3-b]pyridine-2-carboxylic acid (24f). 
Purification by flash column chromatography (20:1, EtOAc:MeOH) gave the free base as a 
white solid (18 mg, 24%), which was converted to the hydrochloride salt by dissolving in 
DMSO (2 mL) and 1 M HCl (1 mL) then lyophilised to dryness. 1H NMR (d6-DMSO) δ 
12.33 (s, 1H), 11.28 (s, 1H), 8.48 (d, J = 7.9 Hz, 1H), 8.40 – 8.34 (m, 1H), 8.17 (dd, J = 
7.9/1.4 Hz, 1H), 7.78 – 7.72 (m, 2H), 7.48 (d, J = 8.6 Hz, 1H), 7.23 – 7.15 (m, 2H), 4.58 (d, J 
= 15.0 Hz, 1H), 4.30 (dd, J = 15.8/7.9 Hz, 1H), 3.82 – 3.73 (m, 3H), 3.41 – 3.06 (m, 5H), 
1.98 – 1.69 (m, 6H), 1.47 – 1.32 (m, 3H), 1.16 – 1.04 (m, 2H). 13C NMR (d6-DMSO) δ 159.4 
(C), 146.9 (C), 143.9 (CH), 137.8 (C), 132.9 (C), 131.3 (CH), 130.9 (CH), 130.7 (CH), 130.4 
(C), 129.8 (CH), 120.1 (C), 118.6 (C), 116.4 (CH), 109.3 (C), 102.3 (CH), 53.5 (CH2), 50.8 
(CH2), 48.2 (CH), 48.0 (CH2), 34.3 (CH), 31.9 (CH2), 31.3 (CH2), 31.2 (CH2), 30.0 (CH2), 
25.2 (CH2). HRMS (m/z): [MH]
+ calcd. for C26H29N5O, 428.2445; found 428.2444 
N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-
pyrrole-2-carboxamide (26). To a solution of 2-(2-((trans)-4-aminocyclohexyl)ethyl)-
1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (11a) (50 mg, 176 µmol) in DCM (15 mL) was 
added pyrrole-2-carboxylic acid (22 mg, 194 µmol), 4-dimethylaminopyridine (4.3 mg, 35 
µmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (37 mg, 194 
µmol), and the brown solution stirred at RT. After 1 h, water (20 mL) was added, then the 
organic layer washed with 1 M  K2CO3 (2 × 20 mL), brine (20 mL) and dried over Na2SO4 
and concentrated in vacuo. The product was purified by flash column chromatography 
Page 49 of 80
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 
 
(EtOAc, gradient to 20:1, EtOAc:MeOH, v/v) to give 32 as a white solid (27 mg, 41%). 1H 
NMR δ 9.52 (br s, 1H), 7.40 (dd, J = 7.9/1.6 Hz, 1H), 7.33 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 
6.90 (td, J = 2.7/1.3 Hz, 1H), 6.51 (ddd, J = 3.7/2.5/1.3 Hz, 1H), 6.22 (dt, J = 3.7/2.6 Hz, 1H), 
5.66 (d, J = 8.2 Hz, 1H), 3.96 – 3.81 (m, 1H), 3.63 (s, 2H), 2.95 (t, J = 5.8 Hz, 2H), 2.75 (t, J 
= 5.8 Hz, 2H), 2.61 – 2.49 (m, 2H), 2.13 – 2.01 (m, 2H), 1.88 – 1.80 (m, 2H), 1.52 (dd, J = 
15.1/6.8 Hz, 2H), 1.41 – 1.07 (m, 5H). 13C NMR δ 160.4 (C), 140.4 (C), 136.4 (C), 130.6 
(CH), 129.8 (CH), 129.7 (CH), 126.4 (C), 121.3 (CH), 119.3 (C), 109.8 (CH), 109.6 (C), 
108.3 (CH), 56.2 (CH2), 55.7 (CH2), 50.4 (CH2), 48.6 (CH), 35.4 (CH), 34.1 (CH2), 33.4 
(CH2), 32.0 (CH2), 29.5 (CH2). HRMS (m/z): [MH]
+ calcd. for C23H28N4O, 377.2336; found 
377.2348. 
(R)-N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl) 
pyrrolidine-2-carboxamide (27b). Following General Procedure E using 2-(2-((trans)-4-
aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (11a) as the amine, and 
(R)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid. Purification by flash column 
chromatography (10:1, EtOAc:MeOH, v/v) afforded 27b as a pale yellow oil, which was then 
taken up in DCM (5 mL) and deprotected following General Procedure B. The product was 
purified by flash column chromatography (7:1:0.1, CHCl3:MeOH:NH4OH) to give the title 
compound as a pale yellow oil (18 mg, 15%). 1H NMR δ 7.43 (d, J = 8.6 Hz, 1H), 7.40 (dd, J 
= 7.9/1.6 Hz, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 3.72 – 3.64 (m, 2H), 3.60 (s, 2H), 
3.04 – 2.82 (m, 4H), 2.72 (t, J = 5.9 Hz, 2H), 2.58 – 2.47 (m, 2H), 2.16 – 2.06 (m, 1H), 1.99 – 
1.83 (m, 4H), 1.83 – 1.75 (m, 2H), 1.73 – 1.64 (m, 2H), 1.50 (dd, J = 15.1/6.9 Hz, 2H), 1.33 – 
1.26 (m, 1H), 1.21 – 1.06 (m, 4H). 13C NMR δ 174.4 (C), 140.5 (C), 136.5 (C), 130.5 (CH), 
129.7 (CH), 129.6 (CH), 119.3 (C), 109.5 (CH), 60.7 (CH), 56.2 (CH2), 55.8 (CH2), 50.4 
(CH2), 47.9 (CH), 47.4 (CH2), 35.4 (CH), 34.2 (CH2), 33.2 (CH2)*, 33.1 (CH2)*, 32.04 
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(CH2)*, 32.01 (CH2)*, 30.9 (CH2), 29.6 (CH2), 26.3 (CH2). HRMS (m/z): [MH]
+ calcd. for 
C23H32N4O, 381.2649; found 381.2656. *Extra signals due to different rotameric forms. 
(S)-N-(trans-4-(2-(7-Cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl) 
pyrrolidine-2-carboxamide (28b). Following General Procedure E using 2-(2-((trans)-4-
aminocyclohexyl)ethyl)-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile (11a) as the amine,  
and (S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid. Purification by flash column 
chromatography (10:1, EtOAc:MeOH, v/v) afforded 28b as a pale yellow oil, which was then 
taken up in DCM (5 mL) and deprotected following General Procedure B. The product was 
purified by flash column chromatography (20:1:0.01, CHCl3:MeOH:NH4OH to 5:1:0.1 
CHCl3:MeOH:NH4OH) to give the title compound as a pale yellow oil (22 mg, 23%). 
1H 
NMR δ 7.46 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 7.9/1.6 Hz, 1H), 7.32 (s, 1H), 7.19 (d, J = 7.9 
Hz, 1H), 3.74 (dd, J = 9.1/5.4 Hz, 1H), 3.70 – 3.61 (m, 1H), 3.60 (s, 2H), 3.06 – 2.98 (m, 
1H), 2.98 – 2.85 (m, 3H), 2.72 (t, J = 5.9 Hz, 2H), 2.58 – 2.50 (m, 2H), 2.25 – 2.10 (m, 2H), 
1.98 – 1.85 (m, 3H), 1.84 – 1.76 (m, 2H), 1.76 – 1.65 (m, 2H), 1.50 (dd, J = 15.2/6.9 Hz, 2H), 
1.36 – 1.23 (m, 1H), 1.23 – 1.05 (m, 4H). 13C NMR δ 174.0 (C), 140.5 (C), 136.5 (C), 130.5 
(CH), 129.7 (CH), 129.7 (CH), 119.3 (C), 109.5 (C), 60.7 (CH), 56.2 (CH2), 55.8 (CH2), 50.4 
(CH2), 48.0 (CH), 47.3 (CH2), 35.4 (CH), 34.2 (CH2), 33.3 (CH2)*, 33.1 (CH2)*, 32.04 
(CH2)*, 32.00 (CH2)*, 31.0 (CH2), 29.6 (CH2), 26.2 (CH2). HRMS (m/z): [MH]
+ calcd. for 
C23H32N4O, 381.2649; found 381.2658. *Extra signals due to different rotameric forms. 
Pharmacological Characterization 
Cell Lines and Transfection:  FlpIn CHO cells (Invitrogen, Carlsbad, USA) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
and maintained at 37 °C in a humidified incubator containing 5% CO2. The FlpIn CHO cells 
were transfected with the pOG44 vector encoding Flp recombinase and the pDEST vector 
encoding the wild-type long isoform of the human D2 receptor (D2LR) at a ratio of 9:1 using 
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polyethylenimine as transfection reagent. 24 h after transfection the cells were subcultured 
and the medium was supplemented with 700µg/ml HygroGold as selection agent. Cells were 
grown and maintained in DMEM containing 20 mM HEPES, 5% fetal bovine serum and 200 
µg/mL Hygromycin-B. Cells were maintained at 37 °C in a humidified incubator containing 
5% CO2, 95% O2. For radioligand binding assays when cells were approximately 90% 
confluent, they were harvested and centrifuged (300 g, 3 min). The resulting pellet was 
resuspended in assay buffer (20 mM HEPES, 6 mM MgCl2, 1 mM EGTA, 1 mM EDTA; pH 
7.4), and the centrifugation procedure repeated. The intact cell pellet was then resuspended in 
assay buffer and homogenised using a Polytron homogeniser for three 10-second intervals on 
the maximum setting, with 30-second periods on ice between each burst. The homogenate 
was made up to 30 mL and centrifuged (350 g, 5 min, 4 °C), the pellet discarded and the 
supernatant recentrifuged at 30,000 g for 1 hour at 4 °C. The resulting pellet was resuspended 
in 5 mL assay buffer and the protein content determined using the method of Bradford. The 
homogenate was then separated into 1 mL aliquots and stored frozen at -80 °C until required 
for binding assays. 
 
[
3
H]raclopride binding assay: Cell membranes (D2L-Flp-In CHO, 10 µg) were incubated 
with varying concentrations of test compound in binding buffer (20 mM HEPES, 100 mM 
NaCl, 6 mM MgCl2, 1 mM EGTA, 1 mM EDTA; pH 7.4) containing 0.5 nM of 
[3H]raclopride to a final volume of 0.3 mL and incubated at 37 °C for 3 h. Binding was 
terminated by fast flow filtration over GF/B membrane unifilter plates (Perkin Elmer) using a 
Uniplate 96-well harvester (Perkin Elmer) followed by five washes with ice-cold 0.9% NaCl. 
Bound radioactivity was measured in a MicroBeta2 LumiJET microbeta counter (Perkin 
Elmer). 
 
Page 52 of 80
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 
 
ERK1/2 phosphorylation assay:  FlpIn CHO cells stably expressing the D2LR were seeded 
into 96-well plates at a density of 50,000 cells/well. After 5-7 h, cells were washed with 
phosphate-buffered saline (PBS) and incubated in serum-free DMEM overnight before 
assaying. Initially, time-course experiments were conducted at least twice for each ligand to 
determine the time required to maximally promote ERK1/2 phosphorylation via the 
dopamine D2LR. Concentration-response experiments in the absence or presence of ligand 
were performed at 37 °C in a 200 µL total volume of DMEM containing 20 mM HEPES and 
0.1 % ascorbic acid. Concentration-response stimulation or inhibition curves were generated 
by exposure of the cells to antagonist ligand for 30 min and then dopamine for 5 min. 
Stimulation of cells was terminated by the removal of media and the addition of 100 µL of 
SureFire™ lysis buffer to each well. The plate was agitated for 1-2 min. A 4:1 v/v dilution of 
Lysate:SureFire™ activation buffer was made in a total volume of 50 µL. A 1:100:120 v/v 
dilution of AlphaScreen™ beads:activated lysate mixture:SureFire™ reaction buffer in an 11 
µL total volume was then transferred to a white opaque 384-well Proxiplate™ in the dark. 
This plate was then incubated in the dark at 37 °C for 1.5 h after which time the fluorescence 
signal was measured by a Fusion-TM plate reader (PerkinElmer), using standard 
AlphaScreen™ settings. Data were normalized to the response generated by 10% fetal bovine 
serum. 
 
Data Analysis:  
Radioligand binding data: Competition-binding curves between [3H]raclopride and  1 could 
be fit to the allosteric ternary complex model using the following equation6: 
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 = [][] 	
[]	
[]
                                                   (1) 
     
Where Y is percentage (vehicle control) binding; [A] and [B] are the concentrations of 
[3H]raclopride and 1, respectively; KA and KB are the equilibrium dissociation constants of 
[3H]raclopride and 1, respectively; α is the cooperativity between 1 and [3H]raclopride Values 
of α >1 denote positive cooperativity; values <1 (but >0) denote negative cooperativity, and 
values = 1 denote neutral cooperativity. 
 
Functional data: A logistic equation of competitive agonist-antagonist interaction was 
globally fitted to data from functional experiments measuring the interaction between 
dopamine and all analogues of 1: 
  
 =  +	  !! "#
$%	&'()*+&,	
- []	&'(./01[] 2
34                                                         (2) 
Where s represents the Schild slope for the antagonist, and pA2 represents the negative 
logarithm of the molar concentration of antagonist that makes it necessary to double the 
concentration of agonist needed to elicit the original submaximal response obtained in the 
absence of antagonist.  
Functional data describing the interaction between all 1 analogues and dopamine analyzed 
according to the allosteric ternary complex model. 
        (3) 
E =
Em .[A]
nH
[A]nH + [EC50]
nH
1+
[B]
KB
1+
αβ[B]
KB
 
 
 
 
  
 
 
 
 
  
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Where Em is the maximum possible cellular response, [A] and [B] are the concentrations of 
orthosteric and allosteric ligands, respectively, and KB are the equilibrium dissociation 
constant of the orthosteric and allosteric ligands, αβ is a composite cooperativity parameter 
between the orthosteric and allosteric ligand that includes effects upon othosteric ligand 
affinity and efficacy and nH is the Hill slope of the orthosteric agonist concentration-response 
curve.  Values of α and/or β greater than 1 denote allosteric potentiation, whereas values less 
than 1 (but greater than 0) denote allosteric inhibition.  
For each of the compounds the two equations (models) were then compared for their fit 
using an extra-sum-of-squares F test, whereby the simpler model was selected unless the P 
value was less than 0.05. 
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Abbreviation List 
2-MPP - 1-(2-methoxyphenyl)piperazine  
2,3-DCPP - 1-(2,3-dichlorophenyl)piperazine 
D2R – dopamine D2 receptor 
DA – dopamine 
DIPEA - N,N-diisopropylethylamine 
HCTU - O-(6-chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
THIQ - tetrahydroisoquinoline 
TM - transmembrane 
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Schemes 
Scheme 1. Synthesis of 2,3,4,5-tetrahydro-1H-benzo[c]azepine.a 
 
 
aReagents and conditions: (a) concentrated HCl, NaN3, 0-50 °C, 16 h, basic workup, 61%; (b) 
LiAlH4, THF, reflux, 16 h, 86%.  
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Scheme 2. Synthesis of the trans-cyclohexylene spacer unit and compounds with 
modifications to the 7-CTHIQ head group.a 
  
R1
O
NHR2
NHR5
N
R3
N
S
N
N
N
R5
R4
R1 = OEt, R2 = H
R1 = OEt, R2 = Boc
R1 = H, R2 = Boc
(c)
O
HO
NO2
(a)
(b)
x
N
H
O
H
N
x
(d)
(f)
=
a: R3 = CN
b: R3 = H
c: R3 = F
g:
h:
i: R4 = OCH3, R
5 = H
j: R4 = R5 = Cl
(e)
5
7
6
8
10a-j R5 = Boc;
11a,c-h R5 = H
1 (from 11a)
12b-j
11i-j R5 = H.3HCl
11b R5 = H.2HCl
d: R3 = Cl
e: R3 = Br
f: R3 = CF3
x
H
x
9a-i
 
aReagents and conditions: (a) 10% Pd/C, H2, 60 psi, rt, 3 d, then; EtOH, conc. HCl, reflux, 2 
h, 81%; (b) Boc2O, NEt3, DCM, rt, 2 h, 96%; (c) DIBALH, toluene, −78 °C, 30 min, 99%; 
(d) NaBH(OAc)3, 1,2-DCE, RT, 16-24 h, 14-91%; (e) TFA, DCM, RT, 16 h, followed by 
NH4OH, 80-99% (11a, c-h as free base; 11b as dihydrochloride salt following acidification 
with HCl/Et2O) and 4 M HCl/1,4-dioxane, rt, 95-100% (11i-j as trihydrochlride salt); (f) 1H-
indole-2-carboxylic acid, HCTU, DIPEA, DMF, RT, 16 h, 22-81%.  
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Scheme 3. Synthesis of 1 derivatives (18a-d) with polymethylene spacer units.a 
 
 
 
aReagents and conditions: (a) Boc2O, Et3N, DCM, RT, 24 h, 47–93%; (b) MsCl, Et3N, DCM, 
16 h, RT, 86–93%; (c) 9a, K2CO3, MeCN, reflux, 16 h, 41%; (d) 9a, NEt3, DCM, RT, 16 h, 
14–52%; (e) TFA, DCM, RT, 2-16h, followed by NH4OH, 46-99%; (f) 1H-indole-2-
carboxylic acid, HCTU, DIPEA, DMF, RT, 16 h, 45–79%. 
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Scheme 4. Synthesis of the N-methylated indole-2-carboxamide analogue of 1 (23).a 
 
H
N
O
N
N
N
Me
NHBoc
EtO
O
NBoc
R1
O
Me
(a)
R1 = OEt
R1 = H
(b)
19
20
7
NR2
N
N
Me
R2 = Boc
R2 = H
(d)
22
21
(c)
23
(e)
 
 
aReagents and conditions: (a) MeI, NaH, DMF, 0 °C, 3d, 36%; (b) DIBAL-H, PhMe, -78 °C, 
100%; (c) 9a, NaBH(OAc)3, 1,2-DCE, RT, 37%; (d) TFA, DCM, RT, 16 h, followed by 
NH4OH, 98%; (e) indole-2-carboxylic acid, HCTU, DIPEA, DMF, RT, 16 h, 34%. 
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Scheme 5. Synthesis of analogues of 1 with modifications to the hydrogen-bond donating 
ability of the 1H-indole-2-carboxamide tail group (25a-f).a 
 
 
 
 
aReagents and conditions: (a) benzofuran-2-carboxylic acid (24a), benzoxazole-2-carboxylic 
acid potassium salt (24b), indene-2-carboxylic acid (24c), 1-methylindole-2-carboxylic acid 
(24d), 1H-benzimidazole-2-carboxylic acid (24e), pyrrolo[2,3-b]pyridine-2-carboxylic acid 
(24f), HCTU, DIPEA, DMF, RT, 16 h, 16-79%.  
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Scheme 6. Synthesis of the ring-deleted, pyrrole analogue of 1 (26), and the D- (27b) and L-
proline (28b) analogues of 1 to investigate the impact of steric bulk and ionization on the tail 
group.a 
  
 
 
aReagents and conditions: (a) pyrrole-2-carboxylic acid, EDCI, DMAP, DCM, RT, 1 h, 41%; 
(b) (i) N-Boc-D-proline (for 27a) or N-Boc-L-proline (for 28b), HCTU, DIPEA, DMF, RT, 16 
h; (ii) TFA, DCM, RT, 16 h, followed by NH4OH, 15-23%. 
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Tables and captions 
 
Table 1. Functional Parameters for Analogues of 1 with chemical modifications to the 7-cyano head group 
 
  Radioligand binding: 
[
3
H]raclopride 
pERK1/2 phosphorylation 
Compound X = pKB
a         
(KB, nM) 
Logαb (α) n pKB
c         
(KB, nM) 
Logαβd     
(αβ) 
Schild 
slopee 
n  
1 -CN 
6.45 ± 0.02 
(355) 
-0.68 ± 0.15 
(0.21) 
3 6.11 ± 0.06 
(776) 
-1.23 ± 0.14 
(0.059) 
n/a 6 
12b -H 
6.53 ± 0.14 
(295) 
-1.35 ± 0.06* 
(0.045) 
3 7.06 ± 0.07* 
(87) 
-1.04 ± 0.14 
(0.091) 
n/a 3 
12c -F 
6.61 ± 0.08 
(245) 
-0.95 ± 0.06 
(0.11) 
3 5.98 ± 0.14 
(1047) 
-0.69 ± 0.10* 
(0.20) 
n/a 3 
12d -Cl 
6.83 ± 0.24 
(148) 
-0.85 ± 0.06 
(0.14) 
3 5.68 ± 0.22 
(2090) 
-0.66 ± 0.10* 
(0.22) 
n/a 4 
12e -Br 
6.77 ± 0.16 
(170) 
n/a 3 6.86 ± 0.07* 
(138) 
n/a 
0.64 ± 
0.05 
3 
12f -CF3 
6.12 ± 0.15 
(759) 
n/a 3 6.05 ± 0.17 
(891) 
n/a 
0.74 ± 
0.11 
3 
 
a  Estimate of the negative logarithm of the equilibrium dissociation constant ± standard error of the mean (s.e.m.) 
determined by radioligand binding.  
b Estimate of the logarithm of the net cooperativity factor between the modulator and [3H]raclopride ± standard error of 
the mean (s.e.m.) determined by radioligand binding. 
c Estimate of the negative logarithm of the equilibrium dissociation constant ± standard error of the mean (s.e.m.) 
determined in an pERK1/2 functional assay  
d  Estimate of the logarithm of the net cooperativity factor between the modulator and dopamine ± standard error of the 
mean (s.e.m.) determined in an pERK1/2 functional assay 
e  Schild slope ± standard error of the mean (s.e.m.) 
n/a compound displayed competitive pharmacology with [3H] racloproide and/or dopamine therefore no value of 
cooperativity factor was derived. 
*  Statistically different from corresponding 1 parameter (p < 0.05, one-way ANOVA, Dunnett’s post-hoc test) 
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Table 2. Functional Parameters for Analogues of 1 with chemical modifications to the THIQ orthosteric 
core 
N
H
O
H
N
x
 
  Radioligand binding: 
[
3
H]raclopride 
pERK1/2 phosphorylation 
Compound X =  pKB
a         
(KB, nM) 
Logαb (α) n pKB
c         
(KB, nM) 
Logαβd     
(αβ) 
Schild 
slopee 
n  
1 
 
6.45 ± 0.02 
(355) 
-0.68 ± 0.15 
(0.21) 
3 
6.11 ± 0.06 
(776) 
-1.23 ± 0.14 
(0.059) 
n/a 6 
12g 
 
5.60 ± 0.21* 
(2510) 
-0.74 ± 0.22 
(0.18) 
3 
5.59 ± 0.13 
(2570) 
-0.79 ± 0.12 
(0.16) 
n/a 4 
12h 
 
5.65 ± 0.26 
(2240) 
-1.56 ± 0.08* 
(0.028) 
3 
6.47 ± 0.24 
(339) 
  -0.51 ± 0.10* 
(0.31) 
n/a 3 
12i 
 
8.41 ± 0.11* 
(3.4) 
n/a 3 
  9.59 ± 
0.14* 
(0.257) 
n/a 0.83 ± 0.02 3 
12j 
 
8.28 ± 0.09* 
(5.25) 
n/a 3 
  8.86 ± 
0.13* (1.38) 
n/a 0.57 ± 0.12 3 
 
a  Estimate of the negative logarithm of the equilibrium dissociation constant ± standard error of the mean (s.e.m.) 
determined by radioligand binding.  
b Estimate of the logarithm of the net cooperativity factor between the modulator and [3H]raclopride ± standard error of 
the mean (s.e.m.) determined by radioligand binding.  
c Estimate of the negative logarithm of the equilibrium dissociation constant ± standard error of the mean (s.e.m.) 
determined in an pERK1/2 functional assay. 
d  Estimate of the logarithm of the net cooperativity factor between the modulator and dopamine ± standard error of the 
mean (s.e.m.) determined in an pERK1/2 functional assay. 
e  Schild slope ± standard error of the mean (s.e.m.). 
n/a compound displayed competitive pharmacology with [3H]racloproide and/or dopamine therefore no value of 
cooperativity factor was derived. 
*  Statistically different from corresponding 1 parameter (p < 0.05, one-way ANOVA, Dunnett’s post-hoc test) 
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Table 3. Functional Parameters for Analogues of 1 with chemical modifications to the cyclohexylene 
spacer 
 
 radioligand binding: 
[
3
H]raclopride 
pERK1/2 phosphorylation 
Compound X = pKB
a      
(KB, nM) 
Logαb (α) n pKB
c         
(KB, nM) 
Logαβd  
(αβ) 
Schild 
slopee 
n  
1 - 
6.45 ± 0.02 
(355) 
-0.68 ± 0.15 
(0.21) 
3 
6.11 ± 0.06 
(776) 
-1.23 ± 0.14 
(0.059) 
n/a 6 
18a 1 
6.43 ± 0.29 
(372) 
-1.03 ± 0.38 
(0.093) 
3 
  6.86 ± 0.07* 
(138) 
-1.38 ± 0.11 
(0.042) 
n/a 3 
18b 2 
6.80 ± 0.28 
(158) 
-0.94 ± 0.10 
(0.11) 
3 
  7.09 ± 0.14* 
(81.2) 
-1.32 ± 0.09 
(0.048) 
n/a 4 
18c 3 
6.32 ± 0.17 
(479) 
n/a 3 
 6.88 ± 0.09  
(132) 
n/a 1.27 ± 0.05 3 
18d 4 
6.57± 0.20 
(269) 
-1.05 ± 0.10 
(0.089) 
3 
  7.52 ± 0.28* 
(30.1) 
-1.68 ± 0.35 
(0.021) 
n/a 3 
 
x  no of carbon atoms within methylene linker 
a Estimate of the negative logarithm of the equilibrium dissociation constant ± standard error of the mean (s.e.m.) 
determined by radioligand binding.  
b Estimate of the logarithm of the net cooperativity factor between the modulator and [3H]raclopride ± standard error of 
the mean (s.e.m.) determined by radioligand binding. 
c Estimate of the negative logarithm of the equilibrium dissociation constant ± standard error of the mean (s.e.m.) 
determined in an pERK1/2 functional assay. 
d  Estimate of the logarithm of the net cooperativity factor between the modulator and dopamine ± standard error of the 
mean (s.e.m.) determined in an pERK1/2 functional assay. 
e  Schild slope ± standard error of the mean (s.e.m.). 
n/a compound displayed competitive pharmacology with [3H]racloproide and/or dopamine therefore no value of 
cooperativity factor was derived. 
*  Statistically different from corresponding 1 parameter (p < 0.05, one-way ANOVA, Dunnett’s post-hoc test) 
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Table 4. Functional Parameters for Analogues of 1 with chemical modifications to the 1H-indole-2-
carboxamide allosteric tail 
 
  radioligand binding: 
[
3
H]raclopride 
pERK1/2 phosphorylation 
Compound X =  pKB
a          
(KB, nM) 
Logαb (α) n pKB
c         
(KB, nM) 
Logαβd  
(αβ) 
Schild 
slopee 
n  
1 
 
6.45 ± 0.02 
(355) 
-0.68 ± 0.15 
(0.21) 
3 
6.11 ± 0.06 
(776) 
-1.23 ± 0.14 
(0.059) 
n/a 6 
23 
 
6.93 ± 0.31 
(117) 
-0.41 ± 0.15 
(0.39) 
3 
  7.04 ± 0.26* 
(91.2) 
  -0.57 ± 
0.10* (0.27) 
n/a 3 
25a 
 
6.55 ± 0.23 
(282) 
n/a 3 
  7.74 ± 0.17* 
(18.2) 
n/a 0.51 ± 0.01 3 
25b 
 
6.58 ± 0.15 
(263) 
n/a 3 
  7.74 ± 0.20* 
(18.2) 
n/a 0.66 ± 0.06 5 
25c 
 
6.82 ± 0.06* 
(151) 
n/a 3 
  7.64 ± 0.22* 
(22.9) 
n/a 0.90 ± 0.07 3 
25d 
 
6.82 ± 0.20 
(151) 
n/a 3 
  7.14 ± 0.09* 
(72.4) 
n/a 0.98 ± 0.06 3 
25e 
 
7.09 ± 0.12 
(81.3) 
n/a 3 
6.76 ± 0.15 
(174) 
n/a 1.06 ± 0.07 3 
25f 
 
7.34 ± 0.05* 
(45.7) 
-1.46 ± 
0.11* 
(0.035) 
3 
  7.63 ± 0.13* 
(23.4) 
-1.39 ± 0.16 
(0.041) 
n/a 5 
26 
 
7.24 ± 0.21* 
(57.5) 
n/a 3 
  8.48 ± 0.23* 
(3.31) 
n/a 0.99 ± 0.07 5 
27b 
 
6.74 ± 0.18 
(363) 
n/a 3 
  7.34 ± 0.17* 
(45.7) 
n/a 1.04 ± 0.07 5 
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28b 
 
7.63 ± 0.12* 
(23.4) 
n/a 3 
  7.56 ± 0.27* 
(27.5) 
n/a 1.37 ± 0.14 3 
 
a Estimate of the negative logarithm of the equilibrium dissociation constant ± standard error of the mean (s.e.m.) 
determined by radioligand binding.  
b Estimate of the logarithm of the net cooperativity factor between the modulator and [3H]raclopride ± standard error of 
the mean (s.e.m.) determined by radioligand binding 
c Estimate of the negative logarithm of the equilibrium dissociation constant ± standard error of the mean (s.e.m.) 
determined in an pERK1/2 functional assay. 
d  Estimate of the logarithm of the net cooperativity factor between the modulator and dopamine ± standard error of the 
mean (s.e.m.) determined in an pERK1/2 functional assay. 
e  Schild slope ± standard error of the mean (s.e.m.) 
n/a compound displayed competitive pharmacology with [3H]racloproide and/or dopamine therefore no value of 
cooperativity factor was derived. 
*  Statistically different from corresponding 1 parameter (p < 0.05, one-way ANOVA, Dunnett’s post-hoc test) 
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Figures and captions 
 
 
Figure 1. The proposed binding mode of 1, which displays allosteric pharmacology despite 
containing structural features of a competitive ligand. 1 was found to act via a novel 
mechanism, engaging one protomer of a D2R dimer in a bitopic mode, and negatively 
modulating dopamine (DA) binding and function at the other protomer.20 The red box 
represents the orthosteric-binding portion, while the green oval represents the allosteric-
binding portion of 1. 
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Figure 2.  General overview of structural modifications of 1 investigated in this study. 
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Please refer to pdf labelled ‘figure 3’ for high resolution image. 
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Figure 3:  
a) Competition binding experiments between analogues of 1 and the radiolabeled antagonist 
[3H]raclopride using membranes of FlpIn CHO expressing the hD2LR reveal that some compounds 
(such as 12e shown here) were able to fully inhibit raclopride binding consistent with a competitive 
interaction. These data could be used to derive a value of affinity (KB). Other compounds, exemplified 
by 1, were unable to fully displace [3H]raclopride binding consistent with an allosteric interaction. 
These data could be fit with an allosteric ternary complex model to derive values of affinity (KB) and 
negative cooperativity with [3H]raclopride. 
b) The action of increasing concentrations of 1 upon a dopamine concentration-response curve was 
measured in an assay measuring ERK1/2 phosphorylation  using whole cells expressing the hD2LR. 
Increasing concentrations of 1 caused a limited dextral displacement of the dopamine dose-response 
curve and data were analyzed according to an operational model of allosterism.  
c) The action of increasing concentrations of 12e upon a dopamine concentration-response curve was 
measured in an assay measuring ERK1/2 phosphorylation  using whole cells expressing the hD2LR. 
Increasing concentrations of 12e caused a limitless dextral displacement of the dopamine dose-response 
curve and data were analyzed according to a Gaddum/Schild model of competitive pharmacology.  
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